Malaria: Evidence-Based Clinical Summary

On this page

Quick Reference

RxDrug of choiceArtemether-lumefantrine (uncomplicated); IV Artesunate (severe)

AltAlternativesDihydroartemisinin-piperaquine; Quinine plus Doxycycline

⊘AvoidPrimaquine in G6PD deficiency; Artemether-lumefantrine in the first trimester of pregnancy (relative, ACTs now generally preferred if benefits outweigh risks)

DxTest of choiceThick and thin blood smears (Microscopy)

ScKey scoreBlantyre Coma Scale (pediatric); Glasgow Coma Scale (adult)

→When to referAny sign of severe malaria (altered mental status, respiratory distress, AKI, or parasitemia > 5%)

Fever in a traveler from an endemic area is malaria until proven otherwise; treat severe cases immediately with IV artesunate to reduce mortality.

Malaria is a life-threatening febrile illness caused by obligate intracellular protozoan parasites of the genus [[Plasmodium]], transmitted to humans via the bite of infected female [[Anopheles]] mosquitoes. While five species regularly infect humans—*P. falciparum*, *P.

Overview and Recommendations

Background

•Recognize malaria as a major global health threat, with approximately 250 million cases and over 600,000 deaths annually, disproportionately affecting children under five and pregnant women in sub-Saharan Africa.
•Identify the five primary human pathogens: (most virulent), P. vivax (common in Asia/Americas, forms dormant liver stages), P. ovale (also forms liver stages), P. malariae (72-hour cycle), and P. knowlesi (zoonotic, 24-hour cycle).
•Understand the life cycle involving the female mosquito vector, which injects sporozoites that first infect the liver (exo-erythrocytic cycle) before entering the bloodstream to infect red blood cells (erythrocytic cycle).
•Note the emergence of artemisinin partial resistance (ART-R), particularly in Southeast Asia and parts of Africa, characterized by delayed parasite clearance and mutations in the pfk13 gene.
•Consider host genetic factors that influence disease course, such as (risk of hemolysis with certain drugs), the Duffy-negative phenotype (historically protective against P. vivax), and sickle cell trait (protective against severe P. falciparum).

Evaluation

•Suspect malaria in any patient with an unexplained fever who has lived in or traveled to an endemic region within the last year, even if they took chemoprophylaxis.
•Ask about the pattern of fever paroxysms (chills, high fever, and sweating), though classic 48- or 72-hour cycles are often absent in the early stages or in non-immune individuals.
•Examine for signs of severe disease, including altered mental status (cerebral malaria), respiratory distress (acidotic breathing), jaundice, and spontaneous bleeding or petechiae.
•Order immediate parasitological testing with thick and thin blood smears; the thick smear is used for screening (sensitivity 50–100 parasites/µL), while the thin smear is used for species identification and quantification.
•Utilize Rapid Diagnostic Tests (RDTs) for Histidine-Rich Protein 2 (HRP2) or parasite Lactate Dehydrogenase (pLDH) when microscopy is unavailable, but be aware of false negatives in HRP2-deleted strains.
•Repeat blood smears every 6–12 hours for 48 hours if the initial test is negative but clinical suspicion remains high, as parasitemia can fluctuate significantly.
•Screen for red flags of severe malaria: Glasgow Coma Scale (GCS) < 11, hemoglobin < 7 g/dL, serum creatinine > 3 mg/dL, or blood glucose < 40 mg/dL.
•Perform pulse oximetry on all patients; an SpO2 < 90% is a high-risk marker for mortality and indicates the need for urgent respiratory support.
•Evaluate for (CM) by assessing consciousness using the Blantyre Coma Scale in children or GCS in adults; CM is defined by a GCS < 11 persisting for >1 hour after a seizure.
•Obtain a complete blood count (CBC) to assess for thrombocytopenia and anemia, and a metabolic panel to monitor for acute kidney injury (MAKI) and hypoglycemia.
•Rule out other tropical febrile illnesses such as , , and , which often present with overlapping symptoms.
•Test for using a point-of-care biosensor before initiating radical cure therapy for P. vivax or P. ovale to prevent life-threatening hemolysis.

Management

•Administer intravenous (IV) 2.4 mg/kg at 0, 12, and 24 hours for all cases of severe malaria, regardless of the infecting species.
•Transition to a full 3-day course of oral Artemisinin-based Combination Therapy (ACT) once the patient with severe malaria can tolerate oral intake.
•Treat uncomplicated P. falciparum with oral Artemether-lumefantrine (20/120 mg tablets, weight-based dosing twice daily for 3 days) as the first-line regimen.
•Use Dihydroartemisinin-piperaquine as an alternative ACT in regions with documented resistance to artemether-lumefantrine.
•Provide radical cure for P. vivax and P. ovale by administering Primaquine 0.25–0.5 mg/kg daily for 14 days to eliminate latent liver hypnozoites.
•Ensure G6PD activity is >30% before giving primaquine; in patients with intermediate deficiency (30-70% activity), consider weekly primaquine (0.75 mg/kg) for 8 weeks under close supervision.
•Manage hypoglycemia aggressively with IV Dextrose (e.g., 10% dextrose 5 mL/kg in children) and monitor blood glucose every 4 hours, as quinine and the infection itself can cause profound drops.
•Control seizures with IV Diazepam 0.3 mg/kg or Midazolam 0.1 mg/kg; if seizures recur, escalate to Phenobarbital 20 mg/kg IV.
•Maintain fluid homeostasis using balanced crystalloids (Lactated Ringer's) at 3-4 mL/kg/hr, but avoid aggressive fluid boluses in cerebral malaria unless the patient is in shock to prevent cerebral edema.
•Monitor for delayed post-artesunate hemolysis (PADH), which can occur 1–3 weeks after treatment with IV artesunate, particularly in patients with high initial parasitemia.
•Avoid using artemisinin monotherapy, as this rapidly drives the development of drug resistance.
•Refer all pregnant women with malaria for specialist obstetric and infectious disease consultation, as they are at high risk for severe anemia and placental sequestration.
•Implement Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) in children aged 3–59 months in high-transmission seasonal areas.
•Recommend the R21/Matrix-M or RTS,S/AS01 vaccine for children in endemic regions as part of a multi-tiered prevention strategy.
•Discharge patients only after they have completed at least 24 hours of oral therapy, are afebrile, have a declining parasite count, and can tolerate oral medications and fluids.

Board Review — High Yield

•Cerebral malaria — Defined by GCS < 11 or Blantyre ≤ 2 in the presence of P. falciparum parasitemia.
•Blackwater fever — Severe intravascular hemolysis leading to hemoglobinuria (dark urine), often associated with P. falciparum.
•Schüffner dots — Fine stippling seen in red blood cells infected with P. vivax or P. ovale.
•Banana-shaped gametocytes — Pathognomonic microscopic finding for P. falciparum.
•Hypnozoites — Dormant liver stages of P. vivax and P. ovale responsible for clinical relapses months later.
•Maurer clefts — Membranous sacs seen in P. falciparum-infected erythrocytes used for protein transport.
•Duffy Antigen — The receptor required for P. vivax entry; Duffy-negative individuals (common in West Africa) are largely resistant.
•Sequestration — P. falciparum cytoadherence to vascular endothelium via PfEMP1, causing microvascular obstruction.
•Recrudescence — Reappearance of parasitemia from the blood cycle (due to treatment failure), distinct from relapse (from liver).

Deep Dive — Evidence Details

Epidemiology and Risk Factors

▸Malaria prevalence and transmission can vary substantially between clusters; baseline surveys and transmission models should inform epidemiological study design [201].
▸Asymptomatic or sub-patent infection may be missed by routine surveillance, including among pregnant women in hard-to-reach areas [220].
▸Children younger than 5 years, and potentially those younger than 10 years in seasonal settings, are key populations for chemoprevention and transmission studies [204,206].
▸Cattle may either reduce human exposure through zooprophylaxis or increase transmission through zoopotentiation; spatial context is essential [205].
▸Anaemia, pregnancy, coinfection, severe disease, parasite resistance, and poor-quality medicines are important epidemiological or outcome-related considerations [207,208,209,213,217,219].

! Warning: Do not interpret a negative routine test as excluding malaria in pregnancy or other high-risk settings when asymptomatic or sub-patent infection is plausible; molecular testing may detect infections missed by rapid diagnostic tests or microscopy [220].

HY High Yield: The principal epidemiological modifiers highlighted by the updated evidence are age, pregnancy, anaemia, seasonality, local vector ecology, livestock distribution, coinfection, parasite drug resistance, and access to quality-assured medicines [201,205,208,209,213,219,220].

Distribution and measurement

Malaria epidemiology is highly heterogeneous between and within communities. Transmission intensity, baseline parasite prevalence, seasonality, age structure, intervention coverage, and local vector ecology can differ sufficiently between neighbouring clusters that these characteristics should be incorporated when designing cluster-randomised trials; malaria prevalence surveys can inform trial sample-size calculations alongside transmission models ^[201]. This heterogeneity also means that estimates based only on routinely detected clinical disease may underestimate the true burden, particularly where infections are asymptomatic or sub-patent ^[220].

The available updated evidence is concentrated in sub-Saharan Africa, with additional evidence from India and studies of imported infection in the United Kingdom. In Mali, malaria was assessed in infants aged 4–11 months immediately before and two weeks after village-level administration of a single 20 mg/kg dose of azithromycin or placebo ^[202]. In rural southern Malawi, a randomised trial enrolled infants at 6 months in a malaria-endemic setting to evaluate iron or multiple-micronutrient supplementation given with malaria chemoprevention, reflecting the epidemiological overlap between malaria, anaemia, nutrition, and early childhood vulnerability ^[204]. In Sierra Leone, a prospective cohort enrolled infants aged 6–10 weeks through primary health facilities and investigated causes of hospital admission and severe morbidity or mortality in early life ^[203].

Age, pregnancy, and clinical vulnerability

Young children remain an important risk group for malaria-related morbidity because malaria prevention and clinical outcomes are closely linked to early-life infection, anaemia, and severe disease. Evidence from Uganda used propensity-score matching in children younger than 5 years to estimate the effect of malaria infection on anaemia while addressing socioeconomic and demographic confounding ^[219]. In Burkina Faso, seasonal malaria chemoprevention (SMC) was evaluated in children younger than 5 years and in an expanded group younger than 10 years; the trial measured clinical incidence, parasite carriage, and gametocyte carriage in both targeted and untargeted individuals ^[206]. These findings address not only direct protection in treated children but also possible effects on community transmission.

Pregnancy is a particularly important epidemiological context because infections may be missed by routine diagnostic strategies. In hard-to-reach, malaria-endemic districts of Odisha, India, repeated community surveys in 2019, 2021, and 2024 used rapid diagnostic tests, microscopy, and polymerase-chain-reaction testing to investigate malaria in pregnancy, including asymptomatic or sub-patent infections, and measured maternal haemoglobin ^[220]. Pregnancy-related vulnerability also intersects with the safety of population interventions: two cluster-randomised trials in Mozambique and Kenya assessed adverse pregnancy outcomes after inadvertent periconception exposure to 400 μg/kg ivermectin administered through mass drug administration, an issue relevant to malaria-control campaigns that may occur in reproductive-age populations ^[207].

Environmental and household risk factors

Livestock ownership and spatial distribution may modify malaria risk through competing biological mechanisms. Cattle can provide an alternative blood source that diverts mosquitoes from humans (zooprophylaxis), but may also increase vector abundance or support transmission (zoopotentiation). A spatial analysis using data from a cluster-randomised trial specifically examined cattle around households and neighbouring homes because household-level livestock ownership alone may not capture geographically mediated effects ^[205].

Flooding and population disruption can alter communicable-disease surveillance and may complicate interpretation of local malaria trends. Following the 10 September 2023 dam collapse and catastrophic flooding in eastern Libya, surveillance reports were reviewed from 14 September to 24 December 2023 to describe disease incidence and geographical and temporal patterns; the study concerned post-disaster communicable diseases generally rather than providing a malaria-specific estimate ^[214]. Similarly, studies of HIV-associated multimorbidity in sub-Saharan Africa and loss to follow-up in Sierra Leone provide health-system context but do not establish malaria-specific risk estimates ^[215]^[218].

Coinfection, comorbidity, and severe disease

Malaria coinfections with other infectious agents are epidemiologically relevant because concurrent infections can complicate diagnosis, attribution of symptoms, and clinical management. An umbrella review synthesized systematic-review evidence on worldwide malaria coinfection prevalence and patterns, using ROBIS, adapted GRADE assessment, and overlap analysis across 21 systematic reviews ^[213]. Severe malaria may involve multisystem disease: in Nigerian children, a study of 100 children with severe malaria and 100 age- and sex-matched controls evaluated cardiac systolic and diastolic function by echocardiography, reflecting concern about cardiac dysfunction associated with severe anaemia, endothelial dysfunction, and ischaemia–reperfusion injury ^[217].

Drug resistance and access-related risks

The effectiveness of malaria control is affected by parasite resistance and medicine quality. A systematic review and meta-analysis of studies from sub-Saharan Africa published between 2010 and 2024 examined temporal and spatial prevalence of Plasmodium falciparum antimalarial-resistance markers, including pfk13 and partner-drug resistance markers ^[208]. A separate systematic review of 123 studies from 34 African countries, representing 36,069 medicine samples collected between 2010 and 2025, estimated the burden of substandard and falsified maternal, newborn, child-health medicines and antimalarials ^[209]. Global evidence synthesis found that artemisinin-based combination therapies retained high pooled 28-day adequate clinical and parasitological response despite concern about pfk13-associated artemisinin resistance ^[211]. In the United Kingdom, imported falciparum malaria remains a disproportionate healthcare burden relative to its incidence; a multisite evaluation assessed outpatient management of selected adults with non-severe imported disease ^[210]^C.

Interpretation of related evidence

Evidence on pre-eclampsia in Ghana, prenatal pyrethroid exposure, and infectious symptoms in children contributes to the broader context of maternal health and vector-control exposure but does not by itself quantify malaria incidence or establish malaria-specific causation ^[212]^[216].

Selected epidemiological settings and risk determinants

Domain	Updated evidence	Reference
Transmission heterogeneity	Cluster-specific prevalence and epidemiology should inform trial design	^[201]
Early childhood	Infants and children are central populations for malaria, anaemia, mortality, and chemoprevention studies	[202–204,206,219]
Pregnancy	Molecular testing can identify asymptomatic or sub-patent infection; campaign drug exposure requires pregnancy-safety assessment	^[207]^[220]
Environment	Cattle may produce zooprophylaxis or zoopotentiation	^[205]
Health-system and treatment factors	Resistance markers, substandard medicines, coinfection, and imported disease influence malaria control and outcomes	[208–213]

History and Physical Examination

▸Fever is nonspecific; malaria must be distinguished from bacterial, viral, arboviral, rickettsial, and other causes of acute febrile illness. [224][225][227][229][234]
▸In a severely ill child, oxygen saturation **<90%** is severe hypoxaemia and should trigger urgent referral and assessment for oxygen therapy. [69]
▸Respiratory distress, neurological involvement, hypotension, oliguria, and disseminated intravascular coagulation are high-risk findings, particularly when malaria is complicated by acute kidney injury. [223]
▸Coma in a malaria-endemic setting is not synonymous with cerebral malaria because incidental parasitaemia may coexist with bacterial or viral encephalopathy. [231]
▸Growth, nutritional, antenatal, birth, and post-acute symptom histories may identify malaria-associated morbidity but are not diagnostic of malaria. [64][222][226][232]

Dx Diagnostic Essentials: Do not diagnose malaria from fever, travel history, splenomegaly, or endemic residence alone. Confirm malaria parasitologically when possible and actively evaluate alternative or coexisting infections, especially in patients with coma, respiratory distress, or persistent fever. [61][224][225][230][231][234]

! Warning: Treat impaired consciousness, respiratory distress, oxygen saturation **<90%**, hypotension, oliguria, seizures, or suspected organ dysfunction as emergency findings requiring immediate escalation of care. [69][223]

Clinical context and presenting illness

Malaria should be considered in any patient with an acute febrile illness who lives in, or has recently travelled to, a malaria-endemic area; however, fever is nonspecific and may reflect bacterial, viral, arboviral, rickettsial, or other infections. ^[224]^[225]^C^[227]^[229]^[233]^C^[234] In returning travellers, evaluation is particularly important when fever begins within 30 days of return from a tropical region, although a substantial proportion of patients tested for malaria may ultimately have another diagnosis or remain undiagnosed. ^[229] Acute undifferentiated fever has been defined in one Mali investigation as fever lasting less than 7 days. ^[225]^C

History should establish the timing and pattern of fever, chills or rigors, headache, malaise, myalgia, gastrointestinal symptoms, respiratory symptoms, altered behaviour, seizures, reduced urine output, and bleeding manifestations. The supplied studies identify respiratory distress, neurological involvement, hypotension, oliguria, and disseminated intravascular coagulation as clinically important features in malaria-associated acute kidney injury and predictors of mortality. ^[223] A history of poor oral intake, vomiting, diarrhoea, or inability to drink is particularly relevant when assessing dehydration and severe disease, although these symptoms are not specific to malaria. ^[224]^[234]

The epidemiological history should include residence, recent travel, season, sleeping conditions, housing quality, mosquito exposure, use of insecticide-treated nets or other vector-control measures, prior malaria episodes, antimalarial use, and adherence to treatment. Housing may modify exposure: in a cluster-randomized trial, children living in insect-proof, smoke-free Star Homes had 44% less malaria after 3 years than children living in traditional mud and thatched-roof houses. ^[221] This finding supports documenting household and environmental exposure without using housing history as a substitute for diagnostic testing. ^[221]

A complete medication and comorbidity history is required, including recent antibiotics, antimalarials, immunosuppressive therapy, pregnancy, nutritional status, and chronic renal or neurological disease. Malaria may coexist with another infection: molecular surveillance in febrile children identified dengue serotypes and malaria co-infection in Gabon, while hospital-based studies in Ghana specifically evaluated concurrent malaria and bacteremia. ^[61]^D^[234] In malaria-endemic settings, incidental parasitaemia can complicate interpretation of coma because children with bacterial or viral causes of coma may be misclassified as having cerebral malaria. ^[231]

General examination

Record temperature, heart rate, respiratory rate, blood pressure, oxygen saturation, mental status, capillary refill, hydration, and urine output. Routine pulse oximetry is clinically relevant in severely ill children: the AIRE project classified severe hypoxaemia as oxygen saturation <90%, and hypoxaemic children were assessed for referral, admission, and oxygen therapy. ^[69]^D Respiratory distress should prompt urgent assessment for severe malaria and alternative diagnoses, because respiratory distress syndrome was strongly associated with mortality among patients with malaria-associated acute kidney injury. ^[223]

Assess appearance, level of alertness, ability to sit or drink, work of breathing, pallor, jaundice, cyanosis, peripheral perfusion, oedema, and signs of bleeding. Hypotension and oliguria are danger signs; hypotension and respiratory distress syndrome were among the strongest mortality-associated findings in the systematic review of malaria with acute kidney injury, while oliguria was also significantly associated with death. ^[223] Examine for hepatosplenomegaly when clinically appropriate, but do not infer malaria solely from splenic enlargement or fever because non-malarial febrile illnesses remain common in malaria-endemic settings. ^[224]^[225]^C^[233]^C^[234]

Neurological examination

Assess orientation, behaviour, speech, neck stiffness, focal neurological findings, seizures, and the Glasgow Coma Scale or an age-appropriate coma assessment. Any reduced consciousness or coma requires emergency evaluation for cerebral malaria and competing causes, including bacterial and viral infection. ^[231] Neurological involvement was strongly associated with mortality in patients with malaria-associated acute kidney injury. ^[223] Current candidate biomarkers such as angiopoietin-like 4 and inhibin-βE have been investigated to help distinguish cerebral malaria from other causes of coma, but the clinical examination remains essential because parasitaemia may be incidental. ^[231]

Assessment of children and longer-term findings

In children, document weight, height or length, nutritional status, and growth trajectory when feasible. Malaria has been associated with impaired growth: Tanzanian longitudinal data linked malaria infection with a reduction of approximately 0.14 cm/month in height velocity, and a Malawian cohort examined temporal associations between Plasmodium falciparum infection and subsequent weight-for-age changes in children followed from birth to 24 months. ^[222]^[232] Placental malaria has also been associated with adverse neonatal outcomes, including low birth weight and decreased birth length, and its relationship with postnatal growth through age 5 years has been investigated in Mali. ^[64]^D These findings support careful antenatal, birth, and growth histories but do not establish that growth impairment is specific to malaria. ^[64]^D^[222]^[232]

Persistent symptoms after treatment should be documented rather than assuming recurrent malaria. A prospective traveller study followed patients after confirmed falciparum malaria for symptoms and quality-of-life effects at 1, 3, 6, 12, and 18 months, demonstrating the value of reviewing post-acute fatigue, functional limitation, and psychological or quality-of-life concerns. ^[226]

Diagnostic implications of the examination

Clinical examination should determine urgency and guide testing, not replace parasitological confirmation. In febrile children, malaria rapid diagnostic testing has been assessed alongside C-reactive protein, white blood-cell counts, and sequential PfHRP2/pLDH interpretation to support antibiotic stewardship. ^[230] A negative or positive malaria result should be interpreted with the full clinical picture because dengue, chikungunya, Zika, rickettsial infection, bacteremia, respiratory infection, and other non-malarial febrile illnesses may occur in the same settings. ^[61]^D^[224]^[225]^C^[227]^[230]^[234] Suspected severe malaria requires immediate referral or hospital-level assessment when there is impaired consciousness, respiratory distress, oxygen saturation <90%, hypotension, oliguria, seizures, severe weakness, inability to drink, or other evidence of organ dysfunction. ^[69]^D^[223]

History and examination findings requiring urgent attention

Domain	Findings or thresholds	Clinical significance
Respiratory	Respiratory distress or oxygen saturation <90%	Severe illness; assess urgently for hypoxaemia and need for referral or oxygen. ^[69]^D^[223]
Neurological	Altered consciousness, coma, seizures, or neurological signs	Consider cerebral malaria and alternative causes of coma. ^[223]^[231]
Circulatory	Hypotension, poor perfusion, or shock features	Strongly associated with mortality in malaria-associated acute kidney injury. ^[223]
Renal	Oliguria or markedly reduced urine output	Associated with mortality and possible acute kidney injury. ^[223]
Haematological/systemic	Bleeding manifestations or suspected disseminated intravascular coagulation	Indicates potentially life-threatening disease. ^[223]
Diagnostic context	Positive or negative malaria test in a febrile patient	Interpret with clinical findings because co-infections and non-malarial febrile illnesses occur. ^[61]^D^[224]^[230]^[234]

Clinical Features and Variants

▸Imported malaria may be nonspecific, rapidly progressive and diagnostically confused with other mosquito-borne infections or bacterial sepsis [289,293].
▸Complicated malaria is reported in 15–40% of hospitalised imported cases, but definitions vary and may under-recognise severity in non-immune travellers [296].
▸Plasmodium vivax can cause severe malaria and requires attention to delayed diagnosis and relapse prevention [242,243,295].
▸Severe malaria may involve AKI, neurological disease, epilepsy risk, endothelial dysfunction and cardiac abnormalities [217,235,246,297].
▸Bacterial coinfection should be considered in severe malaria, particularly when clinical features overlap with sepsis [241,291].
▸Malaria can occur after apparently completed chemoprophylaxis, including prolonged mefloquine use during deployment [300].

Dx Diagnostic Essentials: Consider malaria in any febrile traveller or migrant with relevant exposure, even when symptoms are nonspecific; delayed diagnosis is documented for imported *P. falciparum* and *P. vivax* infection [242,289,293].

! Warning: Do not assume that *P. vivax* is invariably uncomplicated: severe disease, AKI, neurological complications and relapse remain clinically important possibilities [235,243,246,295].

CP Clinical Pearl: In severe malaria, assess renal, neurological and cardiac function and consider bacterial coinfection when the clinical course or inflammatory findings are disproportionate or sepsis-like [217,235,241,291].

Clinical spectrum

Malaria is clinically heterogeneous, ranging from uncomplicated febrile illness to rapidly progressive, multisystem disease. Imported malaria is particularly vulnerable to delayed recognition because it occurs in non-endemic settings, overlaps clinically with other mosquito-borne infections and bacterial sepsis, and may be encountered by clinicians with limited recent experience of the disease ^[289]. A five-case series from northern China emphasised that imported Plasmodium falciparum malaria may present with nonspecific manifestations and can progress rapidly to severe disease; metagenomic next-generation sequencing was used as a complementary diagnostic or management tool in selected diagnostically difficult cases ^[293]^C. Delayed diagnosis has also been specifically investigated in P. vivax infection among patients treated in Bangkok, including Thai patients and people from neighbouring countries ^[242].

Among hospitalised imported cases, “complicated malaria” may be reported in 15–40% of patients, although European studies may use broader composite definitions than the 2023 WHO severe-malaria criteria; this may be important because criteria developed in semi-immune populations could under-recognise severity in non-immune travellers ^[296]. A Polish two-centre cohort therefore examined organ-specific complications present at admission and explored a nine-item severity-capture framework for non-immune travellers ^[296].

Species-related variants

P. falciparum remains a major cause of severe imported malaria and was the species studied in the Chinese mNGS case series and in a phase 2a antimalarial trial restricted to acute uncomplicated monoinfection ^[238]^C^[293]^C. However, P. vivax should not be regarded as uniformly benign. A mixed retrospective-prospective study in central Ethiopia specifically evaluated the increasing contribution of P. vivax to severe malaria among adults attending tertiary-hospital emergency departments, using the 2014 WHO severe-malaria criteria ^[295]. In Southeast Asia, delayed diagnosis of P. vivax has been examined in an urban referral setting where malaria is encountered less routinely ^[242].

A defining clinical feature of P. vivax is the possibility of recurrent illness from relapse. In the Peruvian Amazon, a revised radical-cure algorithm incorporated quantitative G6PD testing to guide primaquine or single-dose tafenoquine selection, reflecting the need to prevent relapse while limiting oxidant haemolysis ^[243]^C. The implementation study evaluated provider compliance with this algorithm under routine care rather than redefining the acute clinical phenotype ^[243]^C.

Severe-organ manifestations

Acute kidney injury (AKI) is an important but historically under-recognised complication of severe malaria in children. An individual-participant-data meta-analysis of African children with P. falciparum malaria used KDIGO creatinine-based criteria to identify AKI and model its association with inpatient mortality ^[235]. Prospective follow-up of Ugandan children who survived severe malaria complicated by AKI subsequently assessed long-term kidney function and mortality, indicating that renal complications may extend beyond the acute admission ^[292].

Neurological disease ranges from impaired consciousness and complex seizures without coma to frank cerebral malaria. A prospective Zambian cohort distinguished cerebral malaria from malaria with central nervous system signs without coma and assessed post-malaria epilepsy after hospital discharge ^[246]. Existing estimates place post-malaria epilepsy after paediatric cerebral malaria at approximately 9–16%, while the risk after non-comatose central nervous system disease has been less well characterised ^[246]. Cerebral malaria also involves persistent vascular and endothelial abnormalities: a Ghanaian longitudinal study followed angiopoietin-1, angiopoietin-2 and soluble thrombomodulin during recovery and compared children with cerebral malaria, uncomplicated malaria and controls ^[297].

Cardiac involvement is increasingly recognised in severe paediatric malaria. Echocardiographic assessment in Nigerian children evaluated right- and left-ventricular systolic and diastolic function, including TAPSE and tricuspid regurgitant velocity, in comparison with age- and sex-matched controls ^[217]. Proposed mechanisms include recurrent ischaemia-reperfusion injury, endothelial dysfunction and severe anaemia ^[217]. Cardiac abnormalities should be interpreted alongside treatment and comorbidity history: hydroxychloroquine exposure has been associated with electrical abnormalities and cardiomyopathy in a separate clinical and experimental study, which is relevant when distinguishing drug toxicity from malaria-associated cardiac dysfunction ^[240]^C.

Coinfection and diagnostic overlap

Severe malaria may coexist with community-acquired bacterial infection. A systematic review and meta-analysis specifically assessed acute community-acquired coinfections in adults with parasitologically confirmed severe imported malaria, reflecting the diagnostic overlap between malaria and bacterial sepsis and the frequent use of empirical antibiotics ^[291]. In critically ill children in Kinshasa, a prospective multicentre study likewise investigated severe malaria–bacterial sepsis coinfection because overlapping clinical and biological features may delay antimicrobial therapy ^[241].

Imported, recurrent and prevention-related variants

Post-travel malaria may occur despite chemoprophylaxis. Among South Korean soldiers deployed to South Sudan, laboratory-confirmed postdeployment Plasmodium infection was investigated after reported adherence to weekly mefloquine during a 40-week deployment and for 4 weeks after departure ^[300]. China’s malaria-free status has not eliminated imported disease: a Shandong hospital study examined cases admitted from 2021 to June 2026, including species, travel history, manifestations, laboratory findings and treatment patterns ^[294]^C.

Vaccination changes population-level disease expression rather than producing a distinct acute phenotype. A Cameroon nationwide difference-in-differences study evaluated routine RTS,S/AS01 introduction in 2024 across 42 priority districts, examining severe and uncomplicated malaria, hospitalisation and mortality in children under 5 years ^[298]. Separately, a systematic review of R21/Matrix-M included 11 studies and pooled 12-month clinical-malaria protection estimates from trials, alongside immunogenicity, safety and implementation evidence ^[290]. A single-dose cabamiquine–pyronaridine trial illustrates the operational distinction between uncomplicated and severe P. falciparum disease: eligible participants had microscopically confirmed monoinfection with parasite densities of 1,000–50,000/µL in one study part and 1,000–150,000/µL in another, while severe malaria and mixed infection were excluded ^[238]^C.

Major clinical variants and distinguishing features

Variant	Clinical relevance	Evidence
Uncomplicated P. falciparum malaria	Acute febrile infection without severe-malaria manifestations; trials may restrict enrolment by parasite density and exclude severe or mixed infection.	^[238]^C
Complicated or severe imported malaria	Organ-specific complications may occur at admission; definitions vary between WHO-based and broader European criteria.	^[296]
Cerebral malaria or CNS malaria	Coma, impaired consciousness and/or complex seizures; survivors may develop post-malaria epilepsy.	^[246]
Malaria-associated AKI	KDIGO creatinine-based AKI is associated with acute mortality risk and may have long-term renal consequences.	^[235]^[292]
Severe P. vivax malaria	P. vivax may contribute substantially to severe disease and can relapse without radical cure.	^[243]^C^[295]
Malaria with bacterial coinfection	Concurrent community-acquired bacterial infection can mimic or complicate severe malaria.	^[241]^[291]

Diagnosis and Workup

▸Use microscopy and/or an RDT for suspected acute malaria, but interpret negative HRP2-based results cautiously where pfhrp2/3 deletions are prevalent; consider microscopy or pLDH-based testing. [306]
▸PCR/qPCR can reveal low-density or sub-patent infection, but Plasmodium DNA may persist through day 28 after effective treatment and should not alone define treatment failure. [220,257]
▸In suspected P. vivax exposure, serology may support surveillance for recent infection or hypnozoite risk, whereas acute parasitemia still requires a direct parasite-detection method. [307]
▸Severe malaria with hemolysis, thrombocytopenia, renal injury, and microangiopathic features can mimic TTP; interpret ADAMTS13 and the clinical course in the malaria context. [263]
▸A rising parasite signal after artesunate may represent delayed clearance of non-viable parasites, including in functional hyposplenism, rather than viable treatment failure. [308]
▸Diagnostic quality depends on access, stock availability, training, supervision, and appropriate task sharing for point-of-care testing. [301,304,261]

Dx Diagnostic Essentials: Do not diagnose antimalarial treatment failure from persistent PCR positivity alone. Reassess the patient clinically and, when possible, confirm viable or clearing parasitemia by repeat microscopy or another appropriate parasite-based method. [257,308]

! Warning: In areas with pfhrp2/3 deletions, a negative HRP2-based RDT can be falsely reassuring; use microscopy or an alternative-antigen assay such as pLDH when indicated. [306]

Diagnostic approach

Malaria diagnosis should be interpreted in the context of fever or compatible illness, exposure and transmission setting, pregnancy, age, prior treatment, and the performance limitations of the available test. Recent studies demonstrate that clinically important infections may be missed by routine surveillance: in pregnant women in hard-to-reach areas of Odisha, infection was assessed by rapid diagnostic test (RDT), microscopy, and PCR, specifically to identify asymptomatic or sub-patent infections; molecular testing detected infections not necessarily captured by routine methods. ^[220] Asymptomatic Plasmodium falciparum infection in Kenyan schoolchildren was identified by microscopy and quantitative PCR (qPCR), with repeated assessments at baseline, 4 weeks, and 8 weeks. ^[258]

Initial parasite detection

Use a malaria RDT and/or microscopy for suspected acute infection when available, documenting the species result and, when microscopy is performed, parasite density and parasite stages. Evidence from Ethiopia shows that RDT choice must reflect local parasite biology: HRP2-based tests may be undermined by pfhrp2/3 deletions, whereas lactate dehydrogenase (pLDH)-based tests were evaluated as an alternative across districts with differing deletion frequencies, transmission intensities, and P. vivax co-endemicity. ^[306] A negative HRP2-based RDT therefore should not be treated as definitive where pfhrp2/3 deletions are prevalent or suspected; confirmatory microscopy or an alternative-antigen test is appropriate in that setting. ^[306]

Point-of-care testing can be delivered outside conventional laboratory workflows. In rural Malawi, malaria testing was included in a package of point-of-care tests shifted from healthcare workers to trained lay health workers, and the intervention was evaluated against the preceding healthcare-worker-led model. ^[304] However, implementation depends on staff competence: a survey of healthcare workers in the Republic of Congo found low practical knowledge despite high willingness to use malaria RDTs, supporting structured training, quality assurance, and supervision. ^[261] In remote Madagascar, a cluster-randomised trial included malaria outcomes when evaluating drone delivery of medical commodities to hard-to-reach public facilities, highlighting that diagnostic access is also dependent on preventing commodity stockouts. ^[301]

Molecular tests and interpretation after treatment

PCR or qPCR is useful when parasite density is low, infection is asymptomatic or sub-patent, species confirmation is needed, or molecular surveillance is being conducted. In Odisha, PCR was integrated with RDT and microscopy to investigate hidden malaria in pregnancy. ^[220] In Cambodia, monthly qPCR surveillance over 12 months was used as the reference framework for validating serological markers of recent P. vivax exposure and possible hypnozoite risk. ^[307]

Highly sensitive molecular assays should not routinely be used to judge treatment response. In a prospective cohort of 100 successfully treated patients, P. falciparum DNA remained detectable in samples collected through day 28 in some patients; assays targeting PfvarATS and 18S rRNA were used to distinguish predominantly asexual-stage from pan-stage detection, and persistent nucleic-acid positivity could reflect residual material or gametocyte-associated detection rather than viable treatment failure. ^[257] Thus, persistent PCR positivity after treatment requires clinical assessment and, where possible, repeat microscopy and quantitative parasite evaluation rather than automatic retreatment or a diagnosis of resistance. ^[257]

Species, transmission, and surveillance questions

When P. vivax is possible, a negative single test does not exclude recent infection or hypnozoite carriage. An eight-marker serological panel was evaluated in Cambodia against longitudinal qPCR to identify individuals likely to have recent exposure and potential hypnozoites in a low-transmission setting. ^[307] Serology is therefore a surveillance or risk-stratification tool in this evidence base, not a substitute for detecting acute parasitemia. ^[307]

For malaria in pregnancy, combine parasite testing with hemoglobin measurement and assessment of persistence or recurrence. The Odisha surveys paired malaria testing with hemoglobin measurement using a HemoCue analyser. ^[220] In Northern Uganda, parasite persistence during intermittent preventive treatment was assessed alongside P. falciparum resistance mutations in the dhfr and dhps genes, including N51I, C59R, S108N, I164L, A437G, K540E, and A581G. ^[259]

Severe disease and diagnostic pitfalls

Severe malaria requires urgent evaluation for anemia, thrombocytopenia, jaundice, kidney injury, hemolysis, and neurologic or other organ dysfunction. A case of severe P. falciparum malaria with anemia, thrombocytopenia, hyperbilirubinemia, acute kidney injury, and elevated lactate dehydrogenase mimicked thrombotic thrombocytopenic purpura; markedly reduced ADAMTS13 and microangiopathic features created a diagnostic challenge between malaria-associated microangiopathy and a primary TTP-spectrum disorder. ^[263] If parasitemia rises despite clinical improvement after artesunate, consider delayed clearance of non-viable parasites, particularly with functional hyposplenism, before concluding treatment failure or artemisinin resistance. ^[308]^C

Resistance and follow-up workup

For suspected treatment failure, document the initial species, baseline parasite detection method, treatment and adherence, then repeat microscopy or an equivalent viability-oriented assessment. Genotyping may support surveillance: P. falciparum Pfkelch13 was assessed in Zambia to investigate artemisinin partial resistance, while parasite resistance markers were examined in Kenya in relation to breakthrough infections during seasonal chemoprevention. ^[305]^[303] Clinical recurrence after pyronaridine-artesunate has also been studied in relation to the number of previous malaria episodes, emphasizing the value of an accurate treatment history rather than relying only on self-report. ^[302] Mefloquine-dose analyses in artesunate-mefloquine studies evaluated recurrence, parasitological outcomes, and tolerability across 6,761 participants, illustrating why treatment history and regimen details matter when interpreting recurrent parasitemia. ^[256]

Hydroxychloroquine exposure should be recorded when relevant to the differential or treatment history because clinically important electrical abnormalities and cardiomyopathy have been reported in treated patients; electrocardiographic assessment may therefore be indicated when cardiac symptoms or risk factors are present. ^[240]^C

Test selection and interpretation

Clinical question	Useful evidence in the cited studies	Key limitation
Acute suspected malaria	RDT and/or microscopy ^[220]^[306]	HRP2-based RDT performance may be affected by pfhrp2/3 deletions ^[306]
Low-density or asymptomatic infection	PCR/qPCR, including repeated testing ^[220]^[258]	Greater sensitivity does not necessarily establish viable parasites after treatment ^[257]
Recent P. vivax exposure or possible hypnozoites	Validated serological-marker panels with qPCR reference ^[307]	Serology is not direct proof of acute parasitemia ^[307]
Suspected treatment failure	Repeat parasite assessment plus treatment, adherence, and resistance history ^[256]^[302]^[305]^[308]^C	Persistent molecular positivity or delayed clearance may mimic failure ^[257]^[308]^C
Severe or complicated malaria	Parasite testing plus assessment of anemia, platelets, bilirubin, renal function, LDH, and clinical organ dysfunction ^[263]	Malaria-associated microangiopathy may resemble TTP ^[263]

Supportive Care and Complication Management

▸Screen comatose children for alternative causes of febrile coma and use structured neurologic, respiratory, renal, metabolic, and seizure monitoring [157][234].
▸MRI-defined severe brain swelling was studied using a brain-volume score of 6–8, with randomization to early ventilation, 3% hypertonic saline, or usual care; comparative results were not available in the supplied abstract [270].
▸Use individualized fluid resuscitation with repeated reassessment; evidence does not establish a mortality advantage for the fluid strategies compared in pediatric severe infection and shock [151].
▸Treat fever and seizures promptly, but use ibuprofen cautiously when renal impairment or dehydration is possible; the antipyretic trial excluded creatinine above 1.2 mg/dL [153].
▸Follow survivors for cognitive impairment, epilepsy, neurologic deficits, movement disorders, recurrent hospitalization, and chronic kidney disease [150][158][175][239][246][292].

! Warning: Do not use large empiric fluid boluses without repeated reassessment: pulmonary edema, cerebral swelling, respiratory failure, and AKI may complicate severe malaria [151][157][272].

Dx Diagnostic Essentials: Febrile coma should not automatically be attributed to cerebral malaria; pathogen-specific testing and, where available, neuroimaging help identify non-malarial causes [157].

CP Clinical Pearl: Post-discharge surveillance is necessary even after neurologic recovery because epilepsy, cognitive impairment, movement disorders, recurrent hospitalization, and chronic kidney disease may emerge later [150][158][175][246][292].

Immediate stabilization and monitoring

Severe malaria is a medical emergency requiring prompt parenteral antimalarial therapy alongside structured supportive care; the available evidence emphasizes that complications may involve the central nervous system, respiratory system, blood, kidneys, and cardiovascular/metabolic function ^[157]^[272]^C. Reassess airway protection, breathing, circulation, level of consciousness, temperature, urine output, glucose, hemoglobin, renal function, acid–base status, parasitemia, and seizure activity frequently, while actively investigating alternative causes of coma or fever because non-malarial infections and other etiologies may coexist or be misclassified as malaria ^[157]^[234]^[272]^C. In febrile coma, pathogen-specific testing and neuroimaging may identify causes other than cerebral malaria, which is particularly important where malaria prevalence is changing and diagnostic resources are limited ^[157].

Cerebral malaria, coma, and cerebral swelling

Children with cerebral malaria are typically identified by coma, parasitemia, and exclusion of another cause; the recent randomized phase 3 trial enrolled children aged 6 months–12 years with a Blantyre Coma Score of ≤2 and used MRI brain-volume screening ^[270]. Children with severe brain swelling, defined by a brain-volume score of 6–8, were randomized to early intubation and mechanical ventilation, intravenous 3% hypertonic saline, or usual care, with 7-day mortality as the primary outcome ^[270]. These interventions should therefore be regarded as specialized, trial-informed strategies for selected patients with documented marked brain swelling rather than routine treatment for every child with cerebral malaria; the supplied abstract does not provide the comparative outcome results ^[270].

Provide meticulous airway positioning, aspiration precautions, oxygenation and ventilation support, and frequent neurologic observation in coma ^[157]^[270]. Intubation and mechanical ventilation may be required for loss of airway protective reflexes, refractory hypoxemia, or severe neurologic deterioration; where severe brain swelling is demonstrated, early ventilation was specifically studied ^[270]. Avoid unstructured fluid loading and monitor closely for pulmonary edema, worsening cerebral swelling, and impaired renal clearance ^[151]^[272]^C.

Fever and seizures

Temperature and seizures are clinically important because higher maximum temperature and seizures are associated with neurologic sequelae among children surviving central nervous system malaria ^[153]. A randomized trial compared scheduled acetaminophen plus ibuprofen with usual-care acetaminophen administered only when temperature reached 38.5 °C or higher in children aged 2–11 years with CNS malaria; children with creatinine >1.2 mg/dL were excluded, so the safety and applicability of ibuprofen require particular caution in renal impairment ^[153]. The supplied abstract does not report the comparative trial results; antipyretic treatment should therefore be individualized, with renal function and hydration considered before NSAID use ^[153]. Treat seizures promptly according to local pediatric emergency protocols, correct hypoglycemia and major metabolic disturbances, and investigate persistent or recurrent seizures for additional structural, infectious, or post-malaria causes ^[157]^[246].

Fluids, shock, and respiratory complications

Assess perfusion dynamically rather than administering empiric large-volume boluses. A systematic review of 12 pediatric trials involving 3,526 children with severe infection, with or without malaria and shock, evaluated balanced crystalloids versus normal saline, colloids versus saline, restricted versus liberal boluses, and slow versus fast administration; pooled mortality findings did not show a significant difference in the reported comparison ^[151]. Consequently, fluid type, volume, and rate should be guided by perfusion, blood pressure, urine output, lactate, respiratory status, anemia, and cardiac or renal tolerance, with frequent reassessment ^[151]. Respiratory distress is a recognized form of severe malaria and is associated with subsequent healthcare needs after discharge ^[158]. Pulmonary edema and respiratory failure require oxygen, escalation to non-invasive or invasive ventilation when indicated, and avoidance of fluid excess ^[157]^[272]^C.

Anemia, kidney injury, and microangiopathic features

Check hemoglobin and clinical perfusion repeatedly; severe malarial anemia is a major severe-malaria phenotype and, like cerebral malaria, is associated with later cognitive impairment ^[175]^D. Transfuse according to clinical severity and local transfusion protocols, balancing tissue hypoxia against circulatory overload ^[175]^D^[272]^C. Monitor creatinine, electrolytes, acid–base status, fluid balance, and urine output for acute kidney injury (AKI), and involve renal-support services early when standard indications for dialysis are present ^[292]. Prospective follow-up data indicate that pediatric AKI after severe malaria is associated with important long-term kidney and survival outcomes, supporting post-discharge renal surveillance even after apparent recovery ^[292].

Thrombocytopenia, hemolysis, jaundice, and elevated lactate dehydrogenase may accompany severe falciparum malaria and can produce secondary microangiopathic features that resemble thrombotic thrombocytopenic purpura; malaria-associated microangiopathy must be distinguished from primary TTP-spectrum disease before plasma exchange or other disease-specific treatment is undertaken ^[263].

Discharge planning and long-term follow-up

Do not equate hospital discharge with complete recovery. At discharge, assess cognition, behavior, hearing, vision, motor function, speech, gait, nutrition, and seizure history, and document residual deficits for comparison at follow-up ^[239]^[175]^D. In one prospective cohort, neurologic deficits at discharge occurred in 38.9% of children with cerebral malaria versus 9.1% with non-cerebral severe malaria; at 12 months, persistent deficits were uncommon in the reported cohort, but surveillance remained necessary ^[239]. Cerebral malaria and severe malarial anemia were associated with long-term cognitive impairment, whereas other severe-malaria presentations were not associated with the same degree of impairment in the cited cohort ^[175]^D.

Arrange follow-up for recurrent seizures and epilepsy even in children who did not experience coma, because post-malaria epilepsy can occur across the spectrum of severe malaria with neurologic signs ^[246]. Counsel families to return urgently for seizures, altered consciousness, weakness, visual or gait problems, recurrent fever, reduced urine output, edema, or breathing difficulty ^[239]^[246]^[292]. Children surviving severe falciparum malaria have increased post-discharge hospitalization and outpatient-care needs compared with community children, supporting planned clinical review rather than passive follow-up ^[158]. Movement disorders, particularly cerebellar ataxia, have been reported after malaria and may require neurologic assessment and rehabilitation ^[150].

Complication-focused supportive care

Complication or risk	Supportive-care priorities	Evidence
Cerebral malaria/coma	Airway protection, oxygenation, neurologic monitoring, seizure management, and evaluation for alternative coma etiologies	^[157]^[270]
Severe brain swelling	Consider specialized neurocritical care; MRI-selected children with brain-volume score 6–8 were studied with early ventilation, 3% hypertonic saline, or usual care	^[270]
Fever	Trial evidence compared scheduled acetaminophen plus ibuprofen with usual-care acetaminophen at ≥38.5°C; renal function must be considered	^[153]
Shock/respiratory distress	Individualized fluids, frequent reassessment, oxygen, and ventilatory support when needed; avoid fluid overload	^[151]^[158]^[272]^C
AKI	Monitor creatinine, electrolytes, urine output, and fluid balance; plan renal follow-up after discharge	^[292]
Neurologic sequelae	Screen cognition, behavior, motor function, vision, hearing, seizures, and movement disorders; arrange rehabilitation and longitudinal review	^[150]^[175]^D^[239]^[246]

Prevention and Screening

▸Tailor ITN distribution and retention strategies to subnational differences in access, use, and durability. [287]
▸Evaluate larval control for container-breeding Anopheles stephensi, including the 102-container Ethiopian SumiLarv™ 2MR trial. [276]
▸SMC research is addressing directly observed treatment, extension beyond age 5 years, and a fifth monthly cycle. [206,266]
▸Monitor adherence and caregiver engagement because delivery quality affects SMC performance. [286]
▸Use molecular surveillance to track pfdhfr and pfdhps markers of sulfadoxine-pyrimethamine resistance. [278]
▸Consider pregnancy screening strategies that detect asymptomatic or subpatent infection using PCR alongside routine testing. [220]
▸RTS,S vaccination combined with SMC reduces infection complexity, while CIS43LS has shown 80% protection for 4–6 months in controlled human malaria infection studies. [277,288]

! Warning: Do not assume that evidence of field evaluation proves routine efficacy: the supplied abstracts for IR3535 and SumiLarv™ 2MR do not report outcome estimates. [276,285]

HY High Yield: Key thresholds reported in the evidence are SMC age targeting of 3–59 months, CIS43LS protection for 4–6 months, and a proposed CIS43LS protective concentration above 64 μg/mL. [206,286,288]

Prevention strategy

Malaria prevention should combine interventions matched to transmission intensity, seasonality, vector ecology, age, pregnancy status, and local implementation capacity. Cluster-randomised trials are particularly useful for evaluating community-wide malaria interventions because cluster allocation reduces contamination and can estimate both direct and indirect effects; mathematical transmission models combined with baseline prevalence surveys can improve trial power and sample-size planning. ^[201]

Vector control

Insecticide-treated nets (ITNs) remain an important malaria-control intervention, but their impact depends on access, use, and retention. Evidence from six African countries—Burkina Faso, Ghana, Malawi, Mali, Mozambique, and Senegal—shows substantial subnational heterogeneity in these measures, supporting locally tailored distribution strategies rather than assuming that a uniform campaign schedule is optimal. ^[287]^D

Spatial repellents may provide an additional option where insecticide resistance threatens existing approaches. A randomised before-after control-intervention trial in rural Mozambique evaluated household spraying with 3-(N-acetyl-n-butyl) aminopropionic acid ethyl ester (IR3535) against no repellent, using PCR-detected Plasmodium falciparum prevalence in children younger than 5 years as an outcome. ^[285] The available report establishes field evaluation but does not provide outcome estimates in the supplied evidence; IR3535 should therefore be regarded as investigational rather than a universally established replacement for ITNs or indoor residual spraying. ^[285]

The invasive vector Anopheles stephensi breeds in artificial containers and can occur in both urban and rural settings without a clear seasonal abundance peak, creating challenges for conventional seasonal control. ^[276] A habitat-randomised controlled trial in Danan, Ethiopia, allocated 102 large artificial water containers (“birkas”) to SumiLarv™ 2MR containing pyriproxyfen or no treatment to assess control of immature An. stephensi. ^[276] These findings support operational evaluation of larval-source management in container habitats, although the supplied abstract does not report the trial’s efficacy estimates. ^[276]

Chemoprevention in children

Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine is used in African settings with highly seasonal transmission and has traditionally targeted children aged 3–59 months. ^[206]^[286] In Burkina Faso, a three-group cluster-randomised trial compared programmatic SMC in children younger than 5 years, directly observed treatment (DOT) in children younger than 5 years, and DOT extended to children younger than 10 years; outcomes included clinical malaria, parasite carriage, and gametocyte carriage in targeted and untargeted populations. ^[206] In Niger, a quasi-experimental study evaluated adding a fifth monthly SMC cycle to the standard four-cycle strategy during a prolonged transmission season. ^[266]

Delivery quality is central to SMC effectiveness. Caregiver engagement, completion of at-home amodiaquine doses, retention of child record cards, trust, and understanding of SMC are relevant implementation factors. ^[286] Post-discharge malaria chemoprevention is also being evaluated for children recovering from severe anaemia or severe malaria; a Benin cluster-randomised implementation trial is examining delivery strategies and adherence support, reflecting the high post-discharge risk of recurrent illness. ^[251]^D

Iron or multiple-micronutrient supplementation may be combined with malaria chemoprevention in young children living in anaemia-prevalent, malaria-endemic settings. The IRMA randomised clinical trial enrolled 6-month-old infants in rural Malawi to assess functional outcomes and infection safety, addressing concerns that universal iron supplementation could increase infection risk. ^[204]

Prevention in pregnancy

Malaria in pregnancy may be missed by routine surveillance when infections are asymptomatic or subpatent. In hard-to-reach districts of Odisha, India, repeated community surveys used rapid diagnostic tests, microscopy, and PCR to investigate infection and haemoglobin status in pregnant women. ^[220] First-antenatal-visit malaria prevalence can provide a longitudinal indicator of malaria burden in pregnancy and correlate with community prevalence; mechanistic modelling may help recover seasonal clinical-incidence patterns for subnational planning. ^[283]

Sulfadoxine-pyrimethamine remains central to intermittent preventive treatment in pregnancy, intermittent preventive treatment in infancy, and SMC despite widespread antifolate-resistance markers in P. falciparum. ^[278] A systematic review of 95 studies from East and West Africa assessed regional and temporal patterns of pfdhfr and pfdhps mutations and haplotypes associated with SP resistance, supporting routine molecular surveillance when selecting or revising chemoprevention policies. ^[278] A meta-analysis found dihydroartemisinin-piperaquine was associated with lower maternal malaria infection than SP (RR 0.22, 95% CI 0.09–0.55), lower placental infection (RR 0.27, 95% CI 0.08–0.98), and lower maternal anaemia (RR 0.84, 95% CI 0.79–0.89); effects on foetal loss, low birth weight, and preterm birth were not statistically conclusive in the supplied summary. ^[279]

Vaccines, antibodies, and surveillance

Combining RTS,S vaccination with SMC has produced substantial protection over a five-year period in a clinical trial; genotyping of 1,530 samples found less complex infections among participants receiving both interventions than among those receiving either intervention alone. ^[277] Long-acting monoclonal antibodies are an emerging preventive approach: CIS43LS, targeting a conserved region of the P. falciparum circumsporozoite protein, demonstrated 80% protection against liver-stage invasion for 4–6 months in controlled human malaria infection studies, with a proposed protective antibody concentration above 64 μg/mL. ^[288]^D

Health literacy is relevant to prevention because it influences bed-net use, indoor residual spraying uptake, treatment seeking, and medication adherence. A community survey in Gabon assessed these relationships across urban and rural populations. ^[281] Community prevention programmes should also account for conflict-related disruption, socioeconomic determinants identified in multi-country DHS analyses, and the role of community health workers in fragmented rural health systems. ^[282]^[269]^[284]

Practical screening priorities

Screening and surveillance should combine sensitive testing for pregnancy-associated and subpatent infection, molecular monitoring of antifolate resistance, parasite genotyping during vaccine–chemoprevention programmes, and prevalence measurement suitable for cluster-level intervention evaluation. ^[220]^[278]^[277]^[201] These approaches can identify hidden infection, track changing drug susceptibility, and guide geographically tailored prevention. ^[220]^[278]^[287]^D

Prevention and surveillance evidence

Intervention or approach	Population or setting	Evidence and implementation relevance
ITNs	Six African countries	Subnational variation in access, use, and retention supports tailored strategies. ^[287]^D
IR3535 spatial repellent	Rural Mozambique; children <5 years assessed by PCR	Randomised field evaluation; supplied evidence does not report efficacy estimates. ^[285]
SumiLarv™ 2MR with pyriproxyfen	102 artificial containers in Danan, Ethiopia	Habitat-randomised evaluation for invasive Anopheles stephensi. ^[276]
SMC	Burkina Faso and Niger	DOT, extension to children <10 years, and a fifth monthly cycle are under evaluation. ^[206]^[266]
Pregnancy chemoprevention	Africa and other endemic settings	DHP showed lower maternal and placental infection than SP in meta-analysis; resistance surveillance remains important. ^[278]^[279]
Screening and surveillance	Pregnant women, trial populations, endemic communities	PCR, genotyping, ANC1 prevalence, and cluster-level modelling identify hidden burden and guide programmes. ^[220]^[277]^[278]^[283]^[201]

References

[1]
Bonacolta AM, Li L, Del Campo J et al.. “Endosymbiotic Apicomplexans of Marine Holobionts: Microbial Parasites in a Warming Ocean.” Integrative and comparative biology (2026). PMID: 41665867 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
[2]
Nguyễn ĐTD, Lê HG, Võ TC et al.. “Genetic polymorphism and natural selection of apical membrane antigen-1 in Plasmodium malariae isolated from Vietnam.” BMC infectious diseases (2026). PMID: 41776459 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Clinical Features and Variants
[3]
Voges K, Dias GR, Dupim EG et al.. “Anopheles (Kerteszia) cruzii, the main malaria vector in the Brazilian Atlantic Forest, is a complex of at least five cryptic species.” Communications biology (2026). PMID: 41741717 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[4]
Lawal MS, Hayashida K, Sugi T et al.. “Detection of novel Pegivirus C genome in an unexplained febrile outbreak, Gombe State, Nigeria, 2024 by enhanced mNGS approach.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41667020 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, History and Physical Examination
[5]
Rubio-Palis Y, Corredor-Medina C, Lenhart AE et al.. “Anopheles species complexes from Guyana and Venezuela malaria endemic areas using COI sequences.” Malaria journal (2026). PMID: 41547760 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[6]
Rattanapitoon NK, Gordon CN, Charoenphon N et al.. “CXCL10high Microglia in Cerebral Malaria: Toward Translational Validation.” CNS neuroscience & therapeutics (2026). PMID: 41518083 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[7]
Daniyan MO, Singh H, Blatch GL. “Plasmodium knowlesi Heat Shock Protein 90s: In Silico Analysis Reveals Unique Druggable Structural Features.” International journal of molecular sciences (2025). PMID: 41465491 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[8]
Traoré H, Gnambani EJ, Hien DFS et al.. “Molecular characterization of potential Plasmodium-Blocking Serratia spp. bacteria in field-caught malaria mosquito in Burkina Faso.” Parasites & vectors (2025). PMID: 41423613 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[9]
Jote K, Gebrehiwot Y, Abebe A et al.. “Preliminary analysis of the conserved Plasmodium falciparum k13 gene in Arbaminch and Mirab Abaya, Ethiopia.” Malaria journal (2025). PMID: 41331631 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[10]
Hossain MS, Anjum MF, Rabbani MA et al.. “Bacillus altitudinis: a sustainable mosquito controlling biopesticide isolated from the rhizospheric soil of Nypa fruticans in mangrove forest.” BMC microbiology (2025). PMID: 41225312 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[11]
Pacheco MA, Miller EA, Harl J et al.. “Haemoproteus syrnii and other haemosporidians infecting owls from North America.” Malaria journal (2025). PMID: 41163075 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[12]
Dharmayanthi AB, Pratama R, Sánchez KL et al.. “The mitochondrial genome sequence of the Bornean orang-utan (Pongo pygmaeus) malaria parasite, Plasmodium pitheci.” Malaria journal (2025). PMID: 41063129 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[13]
Wandera HT, Nattoh G, Kiboi D et al.. “Investigation of prevalence and phylogenetic classification of Microsporidia MB and insecticide target site insensitivity resistance mutations in Anopheles gambiae s.l. and Anopheles funestus mosquitoes from Busia, Kenya.” BMC microbiology (2025). PMID: 41039202 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[14]
Pusawang K, Zhong D, Sriwichai P et al.. “Genetic variation in olfactory pathways associated with host-seeking behavior in natural populations of Anopheles minimus, a primary malaria vector in western Thailand.” Parasites & vectors (2025). PMID: 40993777 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[15]
Teixeira KS, Moreira HM, Roca TP et al.. “Reemergence of Oropouche in the Brazilian Amazon: A phylodynamic and phylogenetic analysis.” Travel medicine and infectious disease (2025). PMID: 40716624 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[16]
Bouyssou I, Golassa L, Vigan-Womas I et al.. “Genomic analysis of Plasmodium vivax field isolates circulating in sub-Saharan Africa.” Communications biology (2025). PMID: 40624365 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[17]
Usmani S, Gebhardt ME, Simubali L et al.. “Phylogenetic taxonomy of the Zambian Anopheles coustani group using a mitogenomics approach.” Malaria journal (2025). PMID: 40597261 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[18]
Kimita G, Collins J, Mutai B et al.. “Detection of zika virus disease caused by the Asian lineage of the zika virus at Kenya's Lamu island.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 40010630 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[19]
Postigo-Hidalgo I, Magassouba N, Krüger N et al.. “Elucidating Infectious Causes of Fever of Unknown Origin: A Laboratory-Based Observational Study of Patients with Suspected Ebola Virus Disease, Guinea, 2014.” The Journal of infectious diseases (2025). PMID: 39928049 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[20]
Bodawatta KH, Albrecht T, Krausová S et al.. “Cophylogeny, narrow host breadth and local conditions drive highly specialized bird-haemosporidian associations in West-Central African sky islands.” Proceedings. Biological sciences (2025). PMID: 39837510 ↗
L5OTHERCited in: Definition, Synonyms, and Classification
[21]
Manu GP, Bonney JHK, Bawa FK et al.. “Reduced COVID-19 severity in Africa: a systematic review of host genetic and immunological responses to SARS-CoV-2 infection.” Frontiers in immunology (2026). PMID: 41993206 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors
[22]
Wilczyńska W, Akilimali A, Korzeniewski K. “Human Filariasis in Africa (2000-2025): Changing epidemiology, uneven diagnostic progress, and persistent neglect.” PLoS neglected tropical diseases (2026). PMID: 41945600 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors
[23]
Sadhewa A, Panggalo LV, Nanine I et al.. “G6PD deficiency in Indonesia: a systematic review and update of prevalence and variant maps in the context of malaria elimination.” The Lancet regional health. Western Pacific (2026). PMID: 41953713 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors
[24]
Hassan U, Siddiqa A, Zhu Y et al.. “Prevalence of Plasmodium falciparum coinfection with Schistosoma haematobium and Schistosoma mansoni among children in sub-Saharan Africa: a systematic review and meta-analysis.” Malaria journal (2026). PMID: 41935296 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Clinical Features and Variants, Diagnosis and Workup
[25]
Penjor K, Thapa B, Tsheten T et al.. “Estimating the burden of imported malaria in the Asia Pacific Region: A Systematic review and meta-analysis.” Journal of travel medicine (2026). PMID: 41934231 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors
[26]
Ramadan S, Talkhan A, Mansour A et al.. “Efficacy of ivermectin for malaria vector control: a systematic review and meta-analysis of randomized clinical trials.” Malaria journal (2026). PMID: 41917922 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors
[27]
Corder RM, Puça MCSB, Prete CA et al.. “Reduced cytochrome P-450 (CYP) 2D6 activity and Plasmodium vivax malaria risk in Amazonians: A retrospective, population-based cohort study.” PLoS neglected tropical diseases (2026). PMID: 41894411 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Management
[28]
Diallo EM, Loum MA, Diallo OO et al.. “Model-Based Assessment of the Effects of Selective Free Healthcare and Differentiated Diagnosis on Malaria Burden in the Republic of Guinea.” Tropical medicine & international health : TM & IH (2026). PMID: 41994979 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Management
[29]
Peng PY, Xu L, Duan HY et al.. “One health perspectives on the epidemiological features and changing incidence of natural focus and vector-borne infectious diseases in China: An observational trend study.” One health (Amsterdam, Netherlands) (2026). PMID: 41993771 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[30]
Rahman MS, Shiddik MAB, Chowdhury AH. “Spatiotemporal patterns of climate-sensitive vector-borne diseases in Bangladesh: leveraging machine learning and spatial regression for intervention strategies.” BMC medicine (2026). PMID: 41975424 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[31]
Barrow A, Barrow S, Bah Y. “Integrated housing quality and insecticide-treated net use: propensity score methods for childhood anemia prevention in The Gambia.” Malaria journal (2026). PMID: 41975408 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[32]
Rios-Teran CA, Tiedje KE, Bangre O et al.. “The dynamics of asymptomatic Plasmodium spp. infections following 10 years of malaria control interventions in Northern Sahelian Ghana.” PLoS neglected tropical diseases (2026). PMID: 41973755 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Prevention and Screening
[33]
Smith SR, Nakibuuka V, Frick KD et al.. “Oxygen blenders for prevention of retinopathy of prematurity are highly cost-effective in Uganda.” Frontiers in medicine (2026). PMID: 41970396 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[34]
Zafindraibe NJ, Razafindrakoto AC, Zemey CB et al.. “Prevalence of malaria during pregnancy and coverage of intermittent preventive treatment with sulfadoxine-pyrimethamine in urban Amboasary-Sud, Southern Madagascar.” Malaria journal (2026). PMID: 41965694 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup
[35]
Addis GT, Addis MT, Mihret Y et al.. “"Referral patterns and associated factors among adult patients admitted with Severe Malaria at Shedeho Meket Primary Hospital, Northeast Ethiopia".” BMC infectious diseases (2026). PMID: 41963834 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Clinical Features and Variants
[36]
Jaramillo-Underwood A, Ogunniyi A, Zhou H et al.. “Risk factors and geospatial associations with Plasmodium falciparum malaria infection and IgG seroprevalence: Nigeria, 2018.” The Journal of infectious diseases (2026). PMID: 41960779 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[37]
Matamanda SH, Musakwa W, Dzomba A. “Malaria at the margins: climatic extremes, migration, and urban informal settlement risk in South Africa.” Malaria journal (2026). PMID: 41952191 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[38]
Ilunga J, Mulenga-Cilundika P, Ekofo J et al.. “Barriers to integration of passive screening for sleeping sickness in Bibanga Health District, Democratic Republic of the Congo.” PLoS neglected tropical diseases (2026). PMID: 41950271 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[39]
Nguyen-Tien T, Tran V, Nguyen TM et al.. “Malaria situation in a highly endemic province in the Central Highlands of Vietnam: a retrospective analysis.” Malaria journal (2026). PMID: 41947165 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[40]
Sekitoleko I, Komata R, Ssali I et al.. “Early-life infectious and nutritional exposures and cardiovascular risk in early adulthood in Uganda: protocol for a new round of data collection in the Entebbe Mother and Baby Study birth cohort at 21 years (EMaBS@21).” BMJ open (2026). PMID: 41946545 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[41]
Belay A, Semahegn A, Hailu BT et al.. “Integration of population-based surveys for neglected tropical diseases: A scoping review.” PLoS neglected tropical diseases (2026). PMID: 41941535 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
[42]
Wynkoop HJ, Lintner-Rivera M, Taylor T et al.. “Malarial pneumonopathy in Malawian children with cerebral malaria.” Malaria journal (2026). PMID: 41935286 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Clinical Features and Variants
[43]
Monteiro GM, Aïkpon RY, Dandonougbo C et al.. “Identification of malaria hotspots in southwestern Benin through spatial joint modelling of malaria incidence and vector abundance.” Malaria journal (2026). PMID: 41935258 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[44]
Tadesse S, Korma W, Sherfa A et al.. “Fatal and non-fatal health outcomes of malaria among reproductive age women in Eastern Sub-Saharan Africa, from 1990 to 2023.” Malaria journal (2026). PMID: 41933334 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[45]
Bennett A, Cotter C, Zarlinda I et al.. “Adapting reactive case detection strategies for high-risk populations to increase malaria infection detection in Aceh Province, Indonesia.” PLOS global public health (2026). PMID: 41931566 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup
[46]
Odibo EO, Nmorsi OPG, Egwunyenga OA et al.. “Haematological responses in children under 5 years with malaria and soil-transmitted helminth coinfections in Delta State, Nigeria: a cross-sectional study.” Therapeutic advances in infectious disease (2026). PMID: 41929652 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[47]
Tsigie M, Baldor L, Feufack-Donfack LB et al.. “Genetic variation in the Duffy blood group among vivax malaria patients and its impact on disease susceptibility.” Malaria journal (2026). PMID: 41928206 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[48]
Yitageasu G, Demoze L. “Spatial epidemiology of malaria by bed net utilization in 19 sub-Saharan African countries: a DHS-based study (2013-2023).” Malaria journal (2026). PMID: 41923227 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[49]
Ladan SM, Lima NP, Orimadegun AE et al.. “Prevalence and inequalities of missed opportunities for intermittent preventive therapy (IPTp) of malaria among pregnant women: an analysis of 2018 Nigeria DHS.” Malaria journal (2026). PMID: 41918116 ↗
L5OTHERCited in: Epidemiology and Risk Factors
[50]
Odongo W, Seffren V, Obiet K et al.. “Community health volunteers improve access to malaria case management in Siaya County, Kenya.” Malaria journal (2026). PMID: 41917974 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup
[51]
Stephenson KB, Greenfeld A, Ryan MG et al.. “Egg supplementation for 24 weeks does not improve linear growth or reduce small intestinal permeability in Sierra Leonean children with moderate wasting: a randomized, blinded, controlled trial.” The American journal of clinical nutrition (2025). PMID: 41193034 ↗
L1bRCTCited in: History and Physical Examination
[52]
Sié A, Ouattara M, Bountogo M et al.. “Mass Azithromycin Distribution and Cause-Specific Mortality among Children Ages 1-59 Months Old: A Secondary Analysis of a Cluster-Randomized Controlled Trial.” The American journal of tropical medicine and hygiene (2026). PMID: 41252743 ↗
L1bRCTCited in: History and Physical Examination
[53]
Saady M, Ewaisha R, Azzazy HME. “Regional burden of undifferentiated fever and leading infectious etiologies of acute febrile illness in low- and middle-income countries: a meta-analysis.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 41161530 ↗
L2aSR_OBSCited in: History and Physical Examination
[54]
Chitrapady S, Rajendran R, K H et al.. “Machine-learning-based artificial intelligence tools for the diagnosis of tropical fevers: a systematic review and meta-analysis protocol of diagnostic test accuracy.” BMJ open (2025). PMID: 40854843 ↗
L2aSR_OBSCited in: History and Physical Examination
[55]
Anselmo A, D'Ugo E, Corrent L et al.. “A case of Human Pegivirus acute febrile infection diagnosed by Next Generation Sequencing (NGS).” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41638349 ↗
L4CASE_REPORTCited in: History and Physical Examination
[56]
Sous M, Boti M, Mose B et al.. “Reversible paralysis in pregnancy, thinking beyond malaria: a case report.” BMC infectious diseases (2025). PMID: 41286642 ↗
L4CASE_REPORTCited in: History and Physical Examination
[57]
Srirama S, Sihag KK, Chandrasekaran AK et al.. “Acute undifferentiated febrile illness in a traveler returning from Burkina Faso, West Africa to Puducherry, India- a case report.” BMC infectious diseases (2025). PMID: 40646441 ↗
L4CASE_REPORTCited in: History and Physical Examination
[58]
Batra P, Kaushik D, Rasane P et al.. “Early-Life Protein Nutrition and Enzymatic Regulation: Mechanistic Pathways Linking Growth Faltering, Stunting, and Obesity.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 41933918 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination
[59]
Abraham P, Lubis IND, Novivanti R et al.. “The household economic burden of human-only and zoonotic malaria, compared to other causes of acute febrile illness in Indonesia.” BMJ global health (2026). PMID: 41887663 ↗
L5OTHERCited in: History and Physical Examination, Diagnosis and Workup
[60]
Sambe BS, Diagne A, Diatta AS et al.. “Malaria misdiagnosis among febrile patients in Senegal: implications for the underestimation of Plasmodium species diversity and malaria burden.” Malaria journal (2026). PMID: 41794727 ↗
L5OTHERCited in: History and Physical Examination
[61]
Moutombi Ditombi BC, Fritz M, Kombila Koumavor CA et al.. “Molecular evidence of co-circulation of different dengue virus serotypes associated with malaria co-infection among febrile children in Libreville, Gabon.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41722758 ↗
L5OTHERCited in: History and Physical Examination
[62]
Lo TQ, Edu-Quansah EP, Dogba J et al.. “Acute febrile illness surveillance using TaqMan Array Cards in two urban health facilities, Monrovia, Liberia, December 2018-March 2020.” PLoS neglected tropical diseases (2026). PMID: 41662363 ↗
L5OTHERCited in: History and Physical Examination
[63]
Arsuaga M, Oliveira-Souto I, Sánchez-Montalvá A et al.. “Travel health risks in adults over 60 years of age: insights from the +Redivi network in Spain.” Journal of travel medicine (2026). PMID: 41614979 ↗
L5OTHERCited in: History and Physical Examination
[64]
Merritt C, Vincenz C, Dolo Z et al.. “Association between placental malaria, postnatal linear growth, and body mass index in the Dogon Longitudinal Study, Mali.” Malaria journal (2026). PMID: 41501807 ↗
L5OTHERCited in: History and Physical Examination
[65]
Chitrapady S, Rajendran R, Haritha K et al.. “Development and evaluation of a diagnostic aiding tool for differentiating tropical fevers using artificial intelligence approach: a study protocol from tertiary care hospital in South India.” BMJ open (2026). PMID: 41490850 ↗
L5OTHERCited in: History and Physical Examination
[66]
Legesse F, Berhane N. “Prevalence of malaria and diagnostic performance of malaria rapid diagnostic tests compared to microscopy among febrile patients at Pawe General Hospital, Northwest Ethiopia.” BMC infectious diseases (2025). PMID: 41449340 ↗
L5OTHERCited in: History and Physical Examination
[67]
Remppis J, Weitz R, Aasi M et al.. “Child health in international travel: A German airport survey.” Travel medicine and infectious disease (2026). PMID: 41386402 ↗
L5OTHERCited in: History and Physical Examination
[68]
Lambebo IH, Eba K, Tucho GT. “Association between climatic conditions and infectious diseases: implications for Central Ethiopia region.” BMC infectious diseases (2025). PMID: 41331557 ↗
L5OTHERCited in: History and Physical Examination
[69]
Hedible KGB, Sawadogo AG, Zair Z et al.. “Care management and determinants of day 14 mortality in severely ill children aged under 5 years subsequent to hypoxaemia diagnosed using routine pulse oximetry in primary care: evidence from the AIRE project.” BMJ global health (2025). PMID: 41309154 ↗
L5OTHERCited in: History and Physical Examination
[70]
Tariq H, Alamgir A, Punar Z et al.. “Climate variability and infectious disease burden in Coastal Sindh, Pakistan: A trend analysis (2019-2022).” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41285193 ↗
L5OTHERCited in: History and Physical Examination
[71]
Kim JH, Chebu P, Fayomade R et al.. “Multi-Pathogen Surveillance of Acute Febrile Illness in Nigeria Using TaqMan Array Cards: Implementation Successes and Lessons Learned From the SAFIAN Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 41263690 ↗
L5OTHERCited in: History and Physical Examination
[72]
Quiner CA, Ephraim AZ, Kwaghe V et al.. “Epidemiology of Plasmodium spp. Detection Among Acute Febrile Illness Patients in Two Regions of Nigeria.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 41263689 ↗
L5OTHERCited in: History and Physical Examination
[73]
Erameh C, Courtney LP, Kwaghe V et al.. “High Burden of Coinfections With Epidemic-Prone Pathogens Among Febrile Patients in Nigeria: A Multi-Pathogen Surveillance Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 41263686 ↗
L5OTHERCited in: History and Physical Examination
[74]
Hedrich N, Lovey T, Bernhard J et al.. “Real-time illness monitoring in travellers: an international, prospective, digital surveillance study.” Travel medicine and infectious disease (2025). PMID: 41260318 ↗
L5OTHERCited in: History and Physical Examination
[75]
Tiberti N, Bertoli G, Mazzi C et al.. “Profiling of circulating immune factors and host-derived extracellular vesicles in response to bacterial or malaria acute fever.” Infection (2026). PMID: 41258581 ↗
L5OTHERCited in: History and Physical Examination
[76]
Abubakr M, Mohamed NS, Sami H et al.. “Epidemiological trends of malaria in Sennar State, Sudan.” Malaria journal (2025). PMID: 41214714 ↗
L5OTHERCited in: History and Physical Examination
[77]
Kaba S, Diallo MDD, Winner MBF. “Influence of community norms on caregivers' early care-seeking behaviour for under-5 children with fever in Guinea, a secondary analysis study.” Malaria journal (2025). PMID: 41084008 ↗
L5OTHERCited in: History and Physical Examination
[78]
Colubri A, Willing N, Grozdani A et al.. “Travel Healthy, a mobile app for participatory surveillance among U.S. international travelers.” Travel medicine and infectious disease (2025). PMID: 41083032 ↗
L5OTHERCited in: History and Physical Examination
[79]
Akanbi DO, Abaye BB, Averhoff F et al.. “Detection of dengue, malaria, and additional causes of acute febrile illness: The need for expanded testing, Bayelsa State, Nigeria.” PLoS neglected tropical diseases (2025). PMID: 41071829 ↗
L5OTHERCited in: History and Physical Examination
[80]
Amoadu M, Alhassan A, Odoom E. “Delay in malaria care-seeking for children under five in Africa: a systematic review.” Malaria journal (2026). PMID: 41845404 ↗
L2aSR_OBSCited in: Clinical Features and Variants
[81]
Meena P, Singla V, Deshpande A et al.. “Clinical characteristics and outcome of malaria-associated acute kidney injury in adult patients: a systematic review and meta analysis.” Malaria journal (2026). PMID: 41620769 ↗
L2aSR_OBSCited in: Clinical Features and Variants
[82]
Okek EJ, Jehopio J, Sande OJ et al.. “Progression from uncomplicated to severe malaria among children in settings receiving different combinations of malaria control interventions in sub-Saharan Africa: a systematic review and meta-analysis.” Tropical medicine and health (2026). PMID: 41862968 ↗
L2aSR_OBSCited in: Clinical Features and Variants
[83]
Riggle BA, Chamzas A, Gopalakrishnan M et al.. “Safety, tolerability, and pharmacokinetics of 6-diazo-5-oxo-L-norleucine (DON) in Malawian adults with and without malaria: a Phase I dose-escalation clinical trial.” The Journal of infectious diseases (2026). PMID: 41748157 ↗
L2bTRIAL_NONRANDOMCited in: Clinical Features and Variants
[84]
Animut A, Bekana T, Siraj SZ et al.. “Treatment outcome and associated factors of severe malaria among admitted children in the Gambella Region, Southwest Ethiopia: a retrospective study design.” Malaria journal (2026). PMID: 41808107 ↗
L2bCOHORTCited in: Clinical Features and Variants, Diagnosis and Workup, Management
[85]
Noor M, Junaid M, Furqan A. “Burden of Plasmodium vivax and Plasmodium falciparum Malaria: clinical insights from a prospective study in Jacobabad, Sindh, Pakistan.” Malaria journal (2026). PMID: 41680751 ↗
L2bCOHORTCited in: Clinical Features and Variants
[86]
Scherer N, Nemerimana M, Nanyunja C et al.. “Early childhood intervention for children at risk of developmental disabilities and their caregivers in Rwanda: study protocol for the PDC/Baby Ubuntu cluster randomised trial.” Trials (2026). PMID: 41862972 ↗
L2bTRIAL_NONRANDOMCited in: Clinical Features and Variants, Diagnosis and Workup, Supportive Care and Complication Management
[87]
Wakai T, Chinedu S, Afolabi I. “Heme oxygenase-1 and malaria pathogenesis.” Frontiers in immunology (2026). PMID: 41836435 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants
[88]
Toure M, Keita S, Keita B et al.. “Trends in malaria indicators in urban and peri-urban areas of Bamako: a scoping review protocol.” Systematic reviews (2026). PMID: 41736077 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants
[89]
Cardona F, Héritier L, Cortaredona S et al.. “Assessment of Long-Term Sequelae After Severe Malaria: A Retrospective Study.” Pathogens (Basel, Switzerland) (2026). PMID: 41754407 ↗
L2bCOHORTCited in: Clinical Features and Variants, Management
[90]
Okullo AE, Ouma S, John CC et al.. “Prevalence and risk factors of gross neurologic deficits in children after severe malaria: A systematic review and meta-analysis.” PloS one (2026). PMID: 41843569 ↗
L2aSR_OBSCited in: Clinical Features and Variants
[91]
Qi YP, Crider KS, Gutman J et al.. “Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.” The Cochrane database of systematic reviews (2026). PMID: 41705996 ↗
L2aSR_OBSCited in: Clinical Features and Variants, Prevention and Screening
[92]
Sastre-Martínez AD, Gutiérrez MAG, Vallejo-Serna RA et al.. “Cerebral malaria caused by Plasmodium vivax in an afrodescendant adult in Colombia: case report.” Malaria journal (2026). PMID: 41851764 ↗
L4CASE_REPORTCited in: Clinical Features and Variants, Management, Supportive Care and Complication Management
[93]
Olwit G, Gutanamuka TB, Chris-Uchendu HC et al.. “Malaria-Associated Acute Kidney Injury: A Key Driver of Mortality in Endemic Regions.” International journal of nephrology and renovascular disease (2026). PMID: 41938719 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants
[94]
Nuin NA, Rajahram GS, Barber BE et al.. “G6PD variants but not Filipino beta-thalassemia are associated with reduced risk of Plasmodium knowlesi infection in Sabah, Malaysia.” Malaria journal (2026). PMID: 41987254 ↗
L5OTHERCited in: Clinical Features and Variants, Diagnosis and Workup
[95]
Lenz T, Sirel M, Hoppe H et al.. “Epigenetics and chromatin structure regulate var2csa expression and the placental-binding phenotype in Plasmodium falciparum.” eLife (2026). PMID: 41984626 ↗
L5OTHERCited in: Clinical Features and Variants
[96]
Klein SG, Mota KCP, Borges BC et al.. “Anti-GPI scFv as a Promising Tool for Intervention Against Cerebral Malaria in Mice.” International journal of molecular sciences (2026). PMID: 41977140 ↗
L5OTHERCited in: Clinical Features and Variants
[97]
Ravishankar K, Mace KE, Koiso S et al.. “Mapping Hospitals That Treat Severe Malaria Cases in the United States: Evidence to Inform Health Systems Strategies for Intravenous Artesunate Supply.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41955078 ↗
L5OTHERCited in: Clinical Features and Variants
[98]
Caiazzo R, Panero B, Carello M et al.. “Pediatric malaria in a non-endemic European setting: clinical patterns, laboratory markers, and the ambiguous role of immunity.” Infection (2026). PMID: 41935227 ↗
L5OTHERCited in: Clinical Features and Variants, Management
[99]
Kasprowicz D, Korzeniewski K, Wilczyńska W. “Clinical Characteristics and Outcomes of Hospitalized Malaria Patients in Rural Madagascar.” Journal of clinical medicine (2026). PMID: 41899312 ↗
L5OTHERCited in: Clinical Features and Variants, Supportive Care and Complication Management
[100]
Bendezu J, Larrauri-Aguilar P, Bautista R et al.. “Phenotypic and genotypic characterization of Plasmodium falciparum field isolates lacking pfhrp2 gene.” Malaria journal (2026). PMID: 41840576 ↗
L5OTHERCited in: Clinical Features and Variants
[101]
Figueroa-Downing D, Kelly SL, Cavelan A et al.. “Timing of the fourth dose of RTS,S/AS01 malaria vaccine in perennial settings: a modelling study.” Malaria journal (2026). PMID: 41827013 ↗
L5OTHERCited in: Clinical Features and Variants
[102]
Chelangat SC, Nakawuki A, Orech S et al.. “Facilitators and barriers to adherence to severe malaria treatment guidelines in children at Mbale Regional Referral Hospital, Uganda: a health workers' perspective.” Malaria journal (2026). PMID: 41749217 ↗
L5OTHERCited in: Clinical Features and Variants
[103]
Diffendall G, Millot P, Chen P et al.. “Longitudinal plasma metabolomics reveals a role for taurine in asymptomatic malaria and seasonal persistence.” Nature microbiology (2026). PMID: 41708949 ↗
L5OTHERCited in: Clinical Features and Variants
[104]
Boopathi PA, Singh S, Roy P et al.. “Comparative clinical transcriptome of pir genes in severe Plasmodium vivax malaria.” PLoS neglected tropical diseases (2026). PMID: 41706749 ↗
L5OTHERCited in: Clinical Features and Variants
[105]
Kanyamukenge DB, Maseko T, Khote FL et al.. “Young children with severe malaria in the Kapolowe health zone: an analysis of their parents' health-seeking behaviors and the challenges they face.” Malaria journal (2026). PMID: 41680770 ↗
L5OTHERCited in: Clinical Features and Variants
[106]
Unnikrishnan G, Singh A. “Diagnostic Accuracy of Point-of-Care Devices for Glucose-6-Phosphate Dehydrogenase Deficiency Detection Among Malaria Patients: A Systematic Review and Meta-Analysis.” Tropical medicine & international health : TM & IH (2026). PMID: 41774916 ↗
L2aSR_OBSCited in: Diagnosis and Workup
[107]
Zambo Bitye BM, Mbianda Nana CM, Kwanou Tchakounte BD et al.. “cTfh Cell Activation and Changes in BTLA and LAG-3 Expression Differentially Associate With Poor Pregnancy Outcome in Plasmodium falciparum Placental Malaria.” Journal of immunology research (2026). PMID: 41983955 ↗
L5OTHERCited in: Diagnosis and Workup
[108]
Pavesi A, Ciccarone A, Logiudice J et al.. “Blood Smear Examination Matters: an Incidental Case of Tick-Borne Relapsing Fever in a Traveller Returning from Senegal.” Travel medicine and infectious disease (2026). PMID: 41974313 ↗
L5OTHERCited in: Diagnosis and Workup
[109]
Chen W, Ochomo E, Muok E et al.. “Modeling and Laboratory Experiments to Assess Detection of Plasmodium falciparum in Wastewater: Insights for Wastewater-Based Surveillance of Malaria.” Environmental science & technology (2026). PMID: 41964709 ↗
L5OTHERCited in: Diagnosis and Workup
[110]
Cavros I, Abanyie F, Kamara ARY et al.. “Efficacy and safety of artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) for the treatment of uncomplicated Plasmodium falciparum malaria among children 6-59 months in three sentinel sites of Sierra Leone, 2021-2022.” Malaria journal (2026). PMID: 41957831 ↗
L5OTHERCited in: Diagnosis and Workup
[111]
Valkiūnas G, Iezhova TA, Chagas CRF et al.. “New experimental insights into the biology of avian malaria parasites.” Malaria journal (2026). PMID: 41952185 ↗
L5OTHERCited in: Diagnosis and Workup
[112]
Adeogun AO, Adetunji O, Babalola AS et al.. “Spatial eco-climatic gradients drive adaptive 2La chromosomal inversion polymorphism in Anopheles coluzzii, a major malaria vector in Nigeria.” International journal of health geographics (2026). PMID: 41943093 ↗
L5OTHERCited in: Diagnosis and Workup
[113]
Cuamba I, Santano R, Grau-Pujol B et al.. “Helminth coinfections mitigate clinical, parasitological, and immune outcomes in Mozambican children with malaria.” BMC medicine (2026). PMID: 41918093 ↗
L5OTHERCited in: Diagnosis and Workup
[114]
Shaba-Santu A, Moonga L, Ogata S et al.. “Prevalence and factors associated with malaria amongst under-five children in Senga Hill District, Northern Province, Zambia, a community-based cross-sectional study.” Malaria journal (2026). PMID: 41917959 ↗
L5OTHERCited in: Diagnosis and Workup
[115]
Maulana T, Marthoenis M, Almira CS et al.. “Socio-demographic characteristics and parasite density patterns of Plasmodium knowlesi Malaria in Aceh, Indonesia: insights from hospital-based data.” Infection (2026). PMID: 41913029 ↗
L5OTHERCited in: Diagnosis and Workup
[116]
Ahogni I, Avanon H, Hueha C et al.. “The accuracy of recording malaria rapid diagnostic test (RDT) results in public health facilities in Benin; results from the MaCRA project.” Malaria journal (2026). PMID: 41904563 ↗
L5OTHERCited in: Diagnosis and Workup
[117]
Jima B, Wondale B, Eligo N et al.. “Microscopy underestimates submicroscopic malaria infections in Ethiopia's southern rift valley: a community-based cross-sectional study.” Malaria journal (2026). PMID: 41904559 ↗
L5OTHERCited in: Diagnosis and Workup
[118]
Li F, Xu O, Zhou J et al.. “Functional characterization of AsOBP21f, an odorant-binding protein involved in human odor detection in the malaria vector Anopheles sinensis.” Parasites & vectors (2026). PMID: 41872964 ↗
L5OTHERCited in: Diagnosis and Workup
[119]
Carey-Ewend K, Shepard H, Yang G et al.. “Frequent Plasmodium ovale recurrence in coastal Tanzania.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41862423 ↗
L5OTHERCited in: Diagnosis and Workup
[120]
Matulis GA, Smith HP, Hall G et al.. “Characterization of arbovirus infections in patients within Haiti by screening discarded malaria rapid diagnostic test cassettes.” PLoS neglected tropical diseases (2026). PMID: 41860982 ↗
L5OTHERCited in: Diagnosis and Workup
[121]
Boadu S, Axame WK, Abanga WA et al.. “Evaluation of malaria rapid diagnostic test kit performance in a high-transmission setting: a facility-based cross-sectional study in rural Ghana.” Malaria journal (2026). PMID: 41857588 ↗
L5OTHERCited in: Diagnosis and Workup
[122]
Pippione AC, Villella N, Fornaseri F et al.. “Structure-based design of new pyrazole inhibitors targeting Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH).” European journal of medicinal chemistry (2026). PMID: 41855879 ↗
L5OTHERCited in: Diagnosis and Workup, Management, Prevention and Screening
[123]
Fenomanana J, Ravoavy A, Rakotoarisoa M et al.. “Field and laboratory evaluation of Abbott-Bioline™ Malaria Ag Pf/Pv RDT performance in a high-transmission setting: contrasting results with a low-endemic area.” Malaria journal (2026). PMID: 41851713 ↗
L5OTHERCited in: Diagnosis and Workup
[124]
Sarma K, Sarma H, Deka J. “Advancing global malaria control: therapeutic strategies, drug discovery, and formulation innovations.” Infection (2026). PMID: 41851575 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup
[125]
Duncombe CJ, Poehlman AS, Conrad EN et al.. “Host biological sex directs immune control of the Plasmodium parasite liver stage in mice.” Frontiers in immunology (2026). PMID: 41846936 ↗
L5OTHERCited in: Diagnosis and Workup
[126]
Mmweteni RE, Philbert AB, Mkandawile G et al.. “Detection of supergroup B Wolbachia strains and their co-infection with Plasmodium falciparum in wild Anopheles funestus in southeastern Tanzania: implications for malaria control.” Parasites & vectors (2026). PMID: 41845520 ↗
L5OTHERCited in: Diagnosis and Workup
[127]
Pfaffendorf C, Dejon-Agobé JC, Edoa JR et al.. “Population pharmacokinetics of fosmidomycin and clindamycin in combination with artesunate for uncomplicated Plasmodium falciparum malaria in Gabonese children and adults.” Malaria journal (2026). PMID: 41857641 ↗
L1bRCTCited in: Management
[128]
Xie K, Otuko R, Marathe A et al.. “Cost and cost-effectiveness of ivermectin mass drug administration for malaria control in Kwale county, Kenya: a modelling analysis of a cluster-randomised trial.” The Lancet. Global health (2026). PMID: 41713445 ↗
L1bRCTCited in: Management, Prevention and Screening
[129]
Ubalde J, Bradshaw C, Fatima SH et al.. “Systematic review of climate change interventions for improving child health.” BMJ paediatrics open (2026). PMID: 41856671 ↗
L2aSR_OBSCited in: Management
[130]
Habarugira F, Batamuriza J, Ndahimana R et al.. “The Global Landscape of Plasmodium falciparum Drug Resistance Markers, 2005-2025: A Systematic Review and Meta-Analysis.” Pathogens (Basel, Switzerland) (2026). PMID: 41754431 ↗
L2aSR_OBSCited in: Management
[131]
Bundi CK, Muñoz O, Kibwana E et al.. “B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.” Frontiers in immunology (2026). PMID: 41846927 ↗
L2bTRIAL_NONRANDOMCited in: Management, Prevention and Screening
[132]
Zhang X, Milligan P, Cheung YB. “Flexible and Interpretable Modeling of Overlapping Exposure Risks in Self-Controlled Case Series Analysis.” Statistics in medicine (2026). PMID: 41979390 ↗
L4CASE_REPORTCited in: Management, Prevention and Screening
[133]
Moriarty LF, Betoulle MM, Troell P et al.. “Antimalarial efficacy monitoring after nearly 20 years of artemisinin-based combination therapy in Africa: recalibrating guidance.” Trends in parasitology (2026). PMID: 41933996 ↗
L5REVIEW_NARRATIVECited in: Management
[134]
Niyomwungere D, Sinarinzi P, Caspar E et al.. “Border Region Surveillance of Malaria Drug Resistance, Northern Burundi, 2023-2024.” Emerging infectious diseases (2026). PMID: 41927306 ↗
L5OTHERCited in: Management
[135]
Ariefta NR, Beteck RM, Legoabe LJ et al.. “Synthetic quinolone-tethered aminoguanidine derivatives exhibit potent antiplasmodial activity.” International journal of antimicrobial agents (2026). PMID: 41921671 ↗
L5OTHERCited in: Management
[136]
Opperman D, Rabie T, Maré M et al.. “Protein Arginine Methyltransferase Inhibitors Target Multiple Stages of Plasmodium falciparum Parasites In Vitro.” ACS infectious diseases (2026). PMID: 41914674 ↗
L5OTHERCited in: Management
[137]
Wu L, Vllasaliu D, Mabayoje DA et al.. “Nanoscaffold-based 3D human liver spheroids for predictive hepatotoxicity screening of antimalarial compounds from the global health priority box.” Parasites & vectors (2026). PMID: 41872940 ↗
L5OTHERCited in: Management
[138]
Rosenthal M, Goldberg DE. “4-Aminoquinolines block heme iron reactivity and interfere with artemisinin action.” eLife (2026). PMID: 41870038 ↗
L5OTHERCited in: Management
[139]
Morgan CJ, Scoullar MJL, Melepia PU et al.. “Women's perspectives on health service integration for multi-morbidity in pregnancy, childbirth, and postpartum in a high-burden setting.” Med (New York, N.Y.) (2026). PMID: 41861824 ↗
L5OTHERCited in: Management
[140]
Aamir M, Rezaee K, Anari MS. “Intelligent in-silico prioritization of antimalarial peptide candidates under explicit physicochemical windows via de novo CTCM-Neo generation and conformal-gated calibrated classification.” Frontiers in cellular and infection microbiology (2026). PMID: 41859462 ↗
L5OTHERCited in: Management
[141]
Khilari A, Sharma S, Bajpai M et al.. “Targeted Genomic Surveillance Unveils Genetic Variations Linked to Regional Malaria Drug Resistance Dynamics in India.” Open forum infectious diseases (2026). PMID: 41846600 ↗
L5OTHERCited in: Management
[142]
Milić M, Obi P, Vanderwal CD et al.. “Polypharmacology in malaria treatment: single drugs, multiple mechanisms, greater impact.” Trends in parasitology (2026). PMID: 41846229 ↗
L5REVIEW_NARRATIVECited in: Management
[143]
Gonçalves AF, Lima-Pinheiro A, Sampaio-Marques B et al.. “Profiling 26S Proteasome Activity of Plasmodium falciparum Monitored by a Live-Cell Assay.” International journal of molecular sciences (2026). PMID: 41828333 ↗
L5OTHERCited in: Management
[144]
Salazar YEAR, Rezende AM, Puça MCSB et al.. “Emergence of artemisinin-based combination therapy resistance markers in Plasmodium falciparum from the Brazilian tri-border region of the Guiana Shield.” Antimicrobial agents and chemotherapy (2026). PMID: 41817181 ↗
L5OTHERCited in: Management
[145]
Moritz A, Hirn-Derksen B, Klein S et al.. “Integrative preclinical strategy for pharmacokinetic profiling and candidate selection of 3-hydroxypropanamidines: a promising antimalarial class.” Malaria journal (2026). PMID: 41808149 ↗
L5OTHERCited in: Management
[146]
Putaporntip C, Somkuna J, Rojrung R et al.. “Contrasting evolutionary trajectories of pyrimethamine resistance in human and zoonotic malaria parasites.” Malaria journal (2026). PMID: 41808095 ↗
L5OTHERCited in: Management
[147]
Vandy A, Turay BA, Lahai M et al.. “Herbal product use in urban slum communities of Freetown, Sierra Leone: Consumption patterns, predictors, and ethnomedicinal applications.” Journal of ethnobiology and ethnomedicine (2026). PMID: 41794856 ↗
L5OTHERCited in: Management
[148]
Abadia ACM, Diedrich D, Vieira LC et al.. “In Vivo Antimalarial Activity and Toxicological Profile of LAFIS10, a Piperazine Derivative From Ursolic Acid.” Tropical medicine & international health : TM & IH (2026). PMID: 41788057 ↗
L5OTHERCited in: Management
[149]
Alemayehu G, Awoke A, Kassa Z. “Ethnobotanical documentation and conservation assessment of medicinal plants used by the Somali community in Karamara forest patches, Eastern Ethiopia.” Journal of ethnobiology and ethnomedicine (2026). PMID: 41787442 ↗
L5OTHERCited in: Management
[150]
Garg RK, Pandey S, Mahdi RA et al.. “Spectrum of movement disorders in Malaria: a systematic review of case reports, case series, and cohort studies.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 40537708 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management
[151]
Sankar J, Das RR, Banothu KK. “Fluid resuscitation in children with severe infection and septic shock: a systematic review and meta-analysis.” European journal of pediatrics (2024). PMID: 38916738 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management
[152]
Casey RM, Najjengo MS, Lubega I et al.. “Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9-23 months old in Uganda, 2019-2020 - Preliminary report.” Vaccine (2024). PMID: 39153293 ↗
L1bRCTCited in: Supportive Care and Complication Management
[153]
Birbeck GL, Seydel KB, Mwanza S et al.. “Acetaminophen and Ibuprofen in Pediatric Central Nervous System Malaria: A Randomized Clinical Trial.” JAMA neurology (2024). PMID: 38857015 ↗
L1bRCTCited in: Supportive Care and Complication Management
[154]
Taylor SM, Korwa S, Wu A et al.. “Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.” PLoS medicine (2022). PMID: 36215323 ↗
L1bRCTCited in: Supportive Care and Complication Management
[155]
Haine V, Oneko M, Debois M et al.. “Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study.” The Lancet. Global health (2025). PMID: 40288377 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management
[156]
Tembo D, Mwanza S, Mwaba C et al.. “Risk factors for acute kidney injury at presentation among children with CNS malaria: a case control study.” Malaria journal (2022). PMID: 36316704 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management
[157]
Ray STJ, Fuller CE, Ahmadu A et al.. “Aetiologies, neuroradiological features, and risk factors for mortality and long-term neurosequelae of febrile coma in Malawian children: a prospective cohort study.” The Lancet. Global health (2025). PMID: 40280145 ↗
L2bCOHORTCited in: Supportive Care and Complication Management
[158]
Opoka RO, Namazzi R, Datta D et al.. “Severe falciparum malaria in young children is associated with an increased risk of post-discharge hospitalization: a prospective cohort study.” Malaria journal (2024). PMID: 39633351 ↗
L2bCOHORTCited in: Supportive Care and Complication Management
[159]
Ranjbar M, Katureebe C, Musanhu CC et al.. “The 24, 2 hours initiative: a game changer in malaria mortality reduction.” Malaria journal (2025). PMID: 41219920 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
[160]
Vathi S, Corriero A, Rodríguez EE et al.. “Management and monitoring strategies for severe cerebral malaria: a guide for the intensivist.” Annals of intensive care (2025). PMID: 41060528 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
[161]
Aderinto N, Abraham IC, Olatunji G et al.. “Stroke incidence, presentation, and outcomes in malaria: a review of current evidence.” Malaria journal (2025). PMID: 40533728 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
[162]
Long B, MacDonald A, Liang SY et al.. “Malaria: A focused review for the emergency medicine clinician.” The American journal of emergency medicine (2024). PMID: 38096639 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
[163]
Tolou-Ghamari Z. “A Review of the Association between Infections, Seizures, and Drugs.” Central nervous system agents in medicinal chemistry (2025). PMID: 38676494 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management
[164]
Deng S, Wang W, Lu W et al.. “Anti-NMDAR encephalitis following malaria: expanding the spectrum of post-malarial neurological syndromes.” Frontiers in immunology (2026). PMID: 41909705 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management
[165]
Kumar A, Agatrao BA, Prakash A et al.. “Malaria-associated splenic haemorrhage requiring emergency splenectomy: a rare complication managed in a resource-constrained setting.” Malaria journal (2026). PMID: 41787355 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management
[166]
Nayak B, Mohanty S, Das S et al.. “Radiological findings in fulminant cerebral malaria: a rare neuroimaging presentation.” Malaria journal (2025). PMID: 41423666 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management
[167]
Huang XA, Xiang R, Liao RH et al.. “Babesia microti (Babesiidae, Piroplasmida) infection in a Chinese traveler returning from the United States of America.” Infectious diseases of poverty (2025). PMID: 40490844 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management
[168]
Wu X, Qin N, Yi F et al.. “Cerebral malaria presenting as nonconvulsive status epilepticus: a case report.” Malaria journal (2024). PMID: 38500090 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management
[169]
Postels DG, Katangwe-Chirwa T. “Cerebral malaria.” Seminars in pediatric neurology (2025). PMID: 40701686 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
[170]
Comino Garcia-Munoz A, Varlet I, Grau GE et al.. “Contribution of Magnetic Resonance Imaging Studies to the Understanding of Cerebral Malaria Pathogenesis.” Pathogens (Basel, Switzerland) (2024). PMID: 39770302 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
[171]
Akafity G, Kumi N, Ashong J. “Diagnosis and management of malaria in the intensive care unit.” Journal of intensive medicine (2024). PMID: 38263976 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
[172]
Toudou-Daouda M. “Epilepsy in Niger: An overview of the current situation.” Epilepsia open (2023). PMID: 37042866 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
[173]
Yacubian EMT, Kakooza-Mwesige A, Singh G et al.. “Common infectious and parasitic diseases as a cause of seizures: geographic distribution and contribution to the burden of epilepsy.” Epileptic disorders : international epilepsy journal with videotape (2022). PMID: 36219093 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
[174]
Fung JST, Hwang B, Dunsmuir D et al.. “A 2-Phase Survey to Assess a Facility's Readiness for Pediatric Essential Emergency and Critical Care in Resource-Limited Settings: A Literature Review and Survey Development.” Pediatric emergency care (2022). PMID: 35981329 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
[175]
Bangirana P, Bond C, Namazzi R et al.. “Cerebral Malaria and Severe Malarial Anemia, but not Other Forms of Severe Malaria, Are Associated With Long-Term Cognitive Impairment.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41631529 ↗
L5OTHERCited in: Supportive Care and Complication Management
[176]
Torres-Fernandez D, Dalsuco J, Garcia-Mauriño C et al.. “Epidemiology and Outcomes of Pediatric Fever in a Rural District of Southern Mozambique: 17 Years of Morbidity Surveillance.” Open forum infectious diseases (2025). PMID: 41394513 ↗
L5OTHERCited in: Supportive Care and Complication Management
[177]
John Mwang'onde B. “Chlorfenapyr-pyrethroid nets for pyrethroid-resistant malaria vectors: efficacy, resistance risks, and policy implications.” Global health action (2026). PMID: 41766494 ↗
L2aSR_OBSCited in: Prevention and Screening
[178]
Tungu PK, Sudi W, Batengana B et al.. “Efficacy of long-lasting insecticidal nets before and after the selection of pyrethroid-resistant Anopheles gambiae s.l. and Anopheles funestus s.l. in northeastern Tanzania: A longitudinal meta-analysis of experimental hut trials at a single location.” Parasites & vectors (2026). PMID: 41742175 ↗
L2aSR_OBSCited in: Prevention and Screening
[179]
Firdaus MH, Ho Imran DS, Puteh SEW et al.. “Strategic resource allocation for malaria elimination in endemic settings: a systematic review of cost-effectiveness evidence.” Frontiers in public health (2025). PMID: 41737900 ↗
L2aSR_OBSCited in: Prevention and Screening
[180]
Tandel N, Thakkar M, Ahuja M et al.. “Poly(I:C) and R848 adjuvants elicit sizeable humoral immunity to liver stage malaria antigens.” Frontiers in immunology (2026). PMID: 41983137 ↗
L5OTHERCited in: Prevention and Screening
[181]
Donassolo RA, Soares da Veiga GT, Nisimura LM et al.. “Naturally acquired antibodies to Plasmodium vivax Pv_LISP-2, a potential liver stage vaccine antigen.” Frontiers in immunology (2026). PMID: 41972120 ↗
L5OTHERCited in: Prevention and Screening
[182]
Su JS, Stover J, Pretorius C et al.. “The benefits of investments to combat HIV, tuberculosis, and malaria for primary healthcare from 2000 to 2023: An economic modeling analysis.” PLoS medicine (2026). PMID: 41950262 ↗
L5OTHERCited in: Prevention and Screening
[183]
Guido G, Totaro V, Lochoro P et al.. “Household and community-based approaches to malaria and cholera prevention: A narrative review with case studies from Uganda and Mozambique.” PLoS neglected tropical diseases (2026). PMID: 41941455 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening
[184]
Zhu Y, Wu S, Qi Y et al.. “Reinventing malaria control: hierarchical intervention strategies for African settings based on the microbiota-barrier-innate immunity axis.” Frontiers in immunology (2026). PMID: 41929484 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening
[185]
Traoré N, Zabré P, Millogo O et al.. “Assessing the role of interventions and climate on malaria mortality among children under five years of age: insights from two decades of data from the Health Demographic Surveillance System of Nouna, Burkina Faso.” Journal of global health (2026). PMID: 41926164 ↗
L5OTHERCited in: Prevention and Screening
[186]
Yahouedo AG, Merle CS, Diallo I et al.. “Climate change and malaria control in Africa: country experiences and strategic responses.” Malaria journal (2026). PMID: 41923083 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening
[187]
Diallo EM, Langlet A, Onyango LA et al.. “Healthcare providers' knowledge, perceptions and practices of malaria control strategies in the Republic of Guinea: insights from a qualitative study.” BMJ global health (2026). PMID: 41916616 ↗
L5OTHERCited in: Prevention and Screening
[188]
Diallo MA, Tine A, Sow D et al.. “Emergence of Plasmodium falciparum pfdhps A581G mutation in Southern Senegal under Seasonal Malaria Chemoprevention pressure, 2020-2023.” Communications medicine (2026). PMID: 41896338 ↗
L5OTHERCited in: Prevention and Screening
[189]
Josue Kedakse TSN, Kaba M, Baonga SF et al.. “Evaluation of the first malaria vaccine introduction: ongoing learning opportunities during the introduction into routine immunisation in Cameroon.” BMJ global health (2026). PMID: 41887666 ↗
L5OTHERCited in: Prevention and Screening
[190]
Lu S, Ding W, Huang L et al.. “The Institution-based Network on China-Africa Cooperation for Malaria Elimination: fostering a transcontinental hub for strengthening China-Africa cooperation on malaria control and elimination efforts.” Infectious diseases of poverty (2026). PMID: 41872959 ↗
L5OTHERCited in: Prevention and Screening
[191]
Mediavilla A, García X, Martínez-Vallejo P et al.. “Molecular markers of antimalarial drug resistance in pfk13, pfmdr1, pfdhfr, and pfdhps genes of Plasmodium falciparum in a rural municipality in Cubal, Benguela Province, Angola (2022-2023).” Malaria journal (2026). PMID: 41840616 ↗
L5OTHERCited in: Prevention and Screening
[192]
Audibert C, Borghini-Fuhrer I, El Gaaloul M et al.. “Improving malaria chemoprevention coverage in pregnancy: Surveying stakeholder preferences for new product profiles and community-delivery approaches across five African countries.” PLOS global public health (2026). PMID: 41824506 ↗
L5OTHERCited in: Prevention and Screening
[193]
Otoo BAF, Opoku-Mireku M, Seaneke SK et al.. “Incidence and trends of adverse drug reactions during seasonal malaria chemoprevention among children: evidence from Ghana's pharmacovigilance database, 2015-2023.” Malaria journal (2026). PMID: 41814293 ↗
L5OTHERCited in: Prevention and Screening
[194]
Ando Y, Mori K, Bradley J et al.. “Determination of the preliminary discriminating concentration of broflanilide against malaria vector mosquito Anopheles gambiae by multi-centre susceptibility testing.” Malaria journal (2026). PMID: 41803905 ↗
L5OTHERCited in: Prevention and Screening
[195]
Dolo AM, Cissoko M, Teme A et al.. “Extreme rainfall, flooding and malaria in the Sahara: outbreak analysis in Kidal, Mali 2024.” Malaria journal (2026). PMID: 41792755 ↗
L5OTHERCited in: Prevention and Screening
[196]
Lake MW, Asemahagn MA, Gelaye KA et al.. “Climate, environmental, and programmatic correlates of malaria resurgence in Amhara, Ethiopia (2018-2024): a Bayesian spatiotemporal analysis.” Malaria journal (2026). PMID: 41782025 ↗
L5OTHERCited in: Prevention and Screening
[197]
Begashaw DT, Alemayehu MA, Animut Y et al.. “Utilization and associated factors of long-lasting insecticide-treated nets among households in Gondar Zuria district, Northwest Ethiopia: a mixed methods study, 2025.” Malaria journal (2026). PMID: 41781949 ↗
L5OTHERCited in: Prevention and Screening
[198]
Rodrigues R, Dhatrak A, Bal M et al.. “Design of an implementation research study for a digital omnichannel community engagement and risk communication intervention for the prevention and control of vector-borne diseases in India: the OMNIVEC-India study protocol.” Frontiers in public health (2025). PMID: 41777371 ↗
L5OTHERCited in: Prevention and Screening
[199]
Laurenson AJ, Pierce BG, Takala-Harrison S et al.. “TEpiNom: A computational framework integrating population data to prioritize Plasmodium falciparum T cell epitopes.” Vaccine (2026). PMID: 41775037 ↗
L5OTHERCited in: Prevention and Screening
[200]
Atijosan A, Atijosan A, Salau AO. “Geospatial mapping of gender-sensitive malaria vulnerability and ITN usage barriers in Zamfara State, Nigeria.” Malaria journal (2026). PMID: 41772643 ↗
L5OTHERCited in: Prevention and Screening
[201]
Challenger JD, Biggs J, Skarp J et al.. “Combining statistical and dynamical modelling to guide the design of cluster randomised trials for malaria.” BMJ global health (2026). PMID: 42665358 ↗
L1bCited in: Epidemiology and Risk Factors
[202]
Ihamuotila R, Juma J, Haidara F et al.. “A single dose of azithromycin versus placebo for malaria in infants: A cluster-randomized trial.” PLOS global public health (2026). PMID: 42623398 ↗
L1bCited in: Epidemiology and Risk Factors
[203]
Owusu-Kyei K, Cussó M, Fombah AE et al.. “Causes of mortality and severe morbidity in young children in Sierra Leone: a prospective cohort study.” The Lancet. Global health (2026). PMID: 42575116 ↗
L1bCited in: Epidemiology and Risk Factors
[204]
Phiri KS, Mzembe G, Vokhiwa M et al.. “Iron or Multiple Micronutrient Powder Supplements With Malaria Chemoprevention in Rural Malawian Children: The IRMA Randomized Clinical Trial.” JAMA (2026). PMID: 42560689 ↗
L1bCited in: Epidemiology and Risk Factors
[205]
Sanz Gutierrez A, Otuko R, Xie K et al.. “Spatial exploration of the impact of cattle on risk of malarial infection using data from a cluster randomised trial.” BMJ global health (2026). PMID: 42547249 ↗
L1bCited in: Epidemiology and Risk Factors
[206]
Yaro JB, Ouedraogo A, Moreno M et al.. “Impact of directly observed treatment and extended age range of seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in Burkina Faso: a three-group, open-label, cluster-randomised, controlled trial.” The Lancet. Infectious diseases (2026). PMID: 42526467 ↗
L1bCited in: Epidemiology and Risk Factors
[207]
Nicolas P, Mundaca H, Brazeal A et al.. “Risk of adverse pregnancy outcomes following inadvertent exposure to ivermectin during the periconception period: findings from two cluster-randomized trials in Mozambique and Kenya.” EClinicalMedicine (2026). PMID: 42518939 ↗
L1bCited in: Epidemiology and Risk Factors
[208]
Towanou Bohissou FE, Wilfried Nassa GJ, Inoue J et al.. “Spatio-temporal trends of the prevalence of Plasmodium falciparum antimalarial drug resistance markers across sub-Saharan Africa from 2010 to 2024: a systematic review and meta-analysis.” BMC infectious diseases (2026). PMID: 42698082 ↗
L2aCited in: Epidemiology and Risk Factors
[209]
Rusatira JC, Novoa MD, Uwimana JB et al.. “Nearly one in five essential medicines fail quality standards in Africa: A systematic review and meta-analysis of MNCH medicines and antimalarials.” PLOS global public health (2026). PMID: 42685013 ↗
L2aCited in: Epidemiology and Risk Factors
[210]
Milburn J, Williamson A, Baljekar S et al.. “Outpatient Management of Imported Nonsevere Falciparum Malaria in Adults in the United Kingdom: A Multisite Evaluation of Clinical Safety and Costing Analysis.” Open forum infectious diseases (2026). PMID: 42621555 ↗
L4Cited in: Epidemiology and Risk Factors
[211]
Ulusan Bağcı Ö, Elhan AH, Akarsu GA. “Efficacy of artemisinin derivatives and kelch13 mutations in Plasmodium falciparum: a systematic review and meta-analysis.” Transactions of the Royal Society of Tropical Medicine and Hygiene (2026). PMID: 42529832 ↗
L2aCited in: Epidemiology and Risk Factors
[212]
Boafo EA, Amponsah RD, Atiase Y et al.. “Pre-Eclampsia Among Pregnant Women in Ghana: A Systematic Review & Meta-Analysis of the Current Prevalence, Risk Factors, and Perinatal Outcomes.” Health science reports (2026). PMID: 42518548 ↗
L2aCited in: Epidemiology and Risk Factors
[213]
Vera-Ponce VJ, Ballena-Caicedo J, Delgado-Toro HE et al.. “Malaria Coinfections Worldwide: An Umbrella Systematic Review of Prevalence and Epidemiological Patterns.” Tropical medicine and infectious disease (2026). PMID: 42506776 ↗
L2aCited in: Epidemiology and Risk Factors
[214]
Alkoshi S, Mohsen A. “Post-flood communicable disease surveillance following the 2023 dam collapse in Eastern Libya.” PLOS global public health (2026). PMID: 42623422 ↗
L3bCited in: Epidemiology and Risk Factors
[215]
Scott R, Olsen CH, Mancuso JD et al.. “Multimorbidity Trajectories and Hospitalization Risk Among People With Human Immunodeficiency Virus in Sub-Saharan Africa: A Longitudinal Analysis From the African Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 42550040 ↗
L3bCited in: Epidemiology and Risk Factors
[216]
Elsiwi B, Eskenazi B, Bornman R et al.. “Maternal exposure to pyrethroid insecticides during pregnancy and repeated measures of infection symptoms among early school-aged children in the Venda Health Examination of Mothers, Babies and their Environment (VHEMBE).” Chemosphere (2026). PMID: 42501461 ↗
L3bCited in: Epidemiology and Risk Factors
[217]
Chinawa JM, Chukwu BF, Okafor HU. “Echocardiographic assessment of cardiac function in children with severe malaria attending two tertiary hospitals in southeast Nigeria.” European journal of pediatrics (2026). PMID: 42498795 ↗
L3bCited in: Epidemiology and Risk Factors
[218]
Fornah L, Osborne A, Shimbre MS et al.. “Incidence and predictors of loss to follow-up after ART initiation at public health facilities in Sierra Leone (2020-2024): a retrospective cohort study.” BMJ open (2026). PMID: 42498473 ↗
L3bCited in: Epidemiology and Risk Factors
[219]
Mwebesa E, Agbi DM, Agasa LO et al.. “Estimating Causal Effects of Malaria Infection on Anaemia Among Children Under Five Years in Uganda: Evidence From a Cross-Sectional Malaria Indicator Survey.” Health science reports (2026). PMID: 42564307 ↗
L2bCited in: Epidemiology and Risk Factors
[220]
Sandeepta S, Rana R, Ghosal J et al.. “Hidden burden of malaria in pregnancy in hard-to-reach areas of Odisha, India: challenges to elimination and the case for integrating molecular surveillance.” Frontiers in public health (2026). PMID: 42682578 ↗
L3bCited in: Epidemiology and Risk Factors
[221]
Mshamu S, Mukaka M, Sanga C et al.. “A sustainable house design to improve child health in rural Africa: a cluster-randomized controlled trial.” Nature medicine (2026). PMID: 42014505 ↗
L1bCited in: History and Physical Examination
[222]
Hiruy HN, Liu E, Worku A et al.. “Associations of Malaria, Diarrhea, and Respiratory Infections with Growth Velocity of Children in Tanzania.” The American journal of tropical medicine and hygiene (2026). PMID: 41946349 ↗
L1bCited in: History and Physical Examination
[223]
Tear AA, Fauziah N, Riswari SF et al.. “Prognostic factors in malaria patients with acute kidney injury: a systematic review and meta analysis.” Renal failure (2026). PMID: 42185742 ↗
L2aCited in: History and Physical Examination
[224]
Ofosu W, Odoom A, Anim-Baidoo I et al.. “Infectious Agents of Non-Malarial Febrile Illnesses in 20 African Countries, 2019-2024: A Systematic Review and Meta-Analysis.” Tropical medicine & international health : TM & IH (2026). PMID: 41983654 ↗
L2aCited in: History and Physical Examination
[225]
Doumbia L, Thirion L, Klitting R et al.. “Study of patients with acute undifferentiated fever identifies dengue as a growing threat to public health in Mali.” PLoS neglected tropical diseases (2026). PMID: 42418522 ↗
L4Cited in: History and Physical Examination
[226]
Hamer DH, Loreau JM, Huits R et al.. “Frequency and persistence of post-acute symptoms after chikungunya, dengue, Zika and malaria in travellers: a prospective multi-centre study.” Journal of travel medicine (2026). PMID: 42149962 ↗
L3bCited in: History and Physical Examination
[227]
Merci M, Dieudonné KO, Nina G et al.. “Rickettsia typhi seroprevalence among patients with unexplained acute fever at the Sourô Sanou University Hospital Center (SSUHC), Burkina Faso.” BMC infectious diseases (2026). PMID: 42032490 ↗
L3bCited in: History and Physical Examination
[228]
Dieci M, Nekesa C, Kayaro NI et al.. “Guideline-concordant care and outcomes for pediatric malaria cases: descriptive evidence from pharmacy-based fever management in Kenya.” Malaria journal (2026). PMID: 41947176 ↗
L3bCited in: History and Physical Examination
[229]
Caronni S, Pieruzzi ME, Salari F et al.. “High rate of undiagnosed cases of fever among returning travelers from tropical areas tested for malaria: a single-center retrospective study.” Travel medicine and infectious disease (2026). PMID: 41812810 ↗
L3bCited in: History and Physical Examination
[230]
Kiemde F, Tahita MC, Rouamba T et al.. “C-reactive protein, white blood cell counts and sequential interpretation of PfHRP2/pLDH for antibiotic stewardship in children under 5 years of age.” BMC infectious diseases (2026). PMID: 41749173 ↗
L3bCited in: History and Physical Examination
[231]
Mwangi S, Gomes C, Abdi AI et al.. “Specific Biomarkers Differentiate Cerebral Malaria From Other Causes of Coma in African Children.” The Journal of infectious diseases (2026). PMID: 41668476 ↗
L3bCited in: History and Physical Examination
[232]
Hosangadi D, Andronescu LR, Mawindo P et al.. “Malaria Incidence, Growth, and their Relationship among a Cohort of Malawian Children.” The American journal of tropical medicine and hygiene (2026). PMID: 42413485 ↗
L2bCited in: History and Physical Examination
[233]
Sabi H, Asuquo D, Attai K et al.. “Risk factors analysis of febrile diseases in LMICs: a case of southern Nigeria.” BMC infectious diseases (2026). PMID: 42045853 ↗
L4Cited in: History and Physical Examination
[234]
Gyasi WA, Boampong K, Sylverken J et al.. “Malaria and bacteremia in febrile children presenting at a teaching hospital in Kumasi, Ghana.” BMC infectious diseases (2026). PMID: 42045840 ↗
L3bCited in: History and Physical Examination
[235]
Bond C, Batte A, Afolayan F et al.. “Identification of acute kidney injury in African children hospitalized with malaria: a multinational individual participant data meta-analysis.” BMC medicine (2026). PMID: 42482088 ↗
L2aCited in: Clinical Features and Variants
[236]
Belete AM, Camara A, Yazie TS et al.. “Transplacental transfer of anti-malarial antibodies: a systematic review.” Frontiers in immunology (2026). PMID: 42404900 ↗
L2aCited in: Clinical Features and Variants
[237]
Ranjan S, Dubey M, Sharma S et al.. “Association of ABO Blood Group and Severe Plasmodium falciparum Malaria: An Updated Meta-Analysis and Trial Sequential Analysis.” Tropical medicine & international health : TM & IH (2026). PMID: 42320994 ↗
L2aCited in: Clinical Features and Variants
[238]
Mombo-Ngoma G, Adoke Y, Manego RZ et al.. “Safety, pharmacokinetics, and antimalarial efficacy of single-dose cabamiquine-pyronaridine combination therapy for the treatment of adults and adolescents with acute uncomplicated Plasmodium falciparum malaria (CAPTURE 1): a prospective, multicentre, open-label, phase 2a study.” The Lancet. Infectious diseases (2026). PMID: 42462745 ↗
L4Cited in: Clinical Features and Variants
[239]
Okullo AE, Idro R, van Hensbroek MB et al.. “Neurologic sequelae of cerebral malaria and other forms of severe malaria in children.” Pediatric research (2026). PMID: 42401781 ↗
L2bCited in: Clinical Features and Variants
[240]
Shiba M, Liu Z, Higo S et al.. “Clinical and Experimental Insights into Hydroxychloroquine-Associated Electrical Abnormalities and Cardiomyopathy.” European heart journal. Cardiovascular pharmacotherapy (2026). PMID: 42637670 ↗
L4Cited in: Clinical Features and Variants
[241]
Monkoti Manzi MG, Nsibu C, Bodi J et al.. “Severe malaria-bacterial sepsis co-infection among critically ill children admitted to pediatric emergency departments in Kinshasa.” World journal of clinical pediatrics (2026). PMID: 42626138 ↗
L3bCited in: Clinical Features and Variants
[242]
Charoensakulchai S, Tangpukdee N, Wilairatana P et al.. “Delayed diagnosis of Plasmodium vivax malaria and associated factors among Thai patients and patients from neighboring countries at the Hospital for Tropical Diseases, Bangkok, Thailand.” Infection (2026). PMID: 42606671 ↗
L3bCited in: Clinical Features and Variants
[243]
Vidal-Cardenas E, De Freitas-Vidal CI, Soto-Calle V et al.. “Health-care provider compliance with a revised Plasmodium vivax radical cure algorithm incorporating tafenoquine and quantitative G6PD testing in the Peruvian Amazon: a prospective observational study.” Lancet regional health. Americas (2026). PMID: 42500357 ↗
L4Cited in: Clinical Features and Variants
[244]
Sha T, Cao Y, Liu K et al.. “Healthcare utilization patterns and diagnostic delays among international migrant workers with imported malaria in China: a retrospective cohort analysis.” Malaria journal (2026). PMID: 42399742 ↗
L3bCited in: Clinical Features and Variants
[245]
Moutombi-Ditombi BC, Lembet Mikolo AM, Ndong Ngomo JM et al.. “Clinical profiles and predictors of intensive care unit transfer among children hospitalized with severe Plasmodium falciparum malaria in a tertiary care hospital in Libreville, Gabon: a retrospective study.” BMC infectious diseases (2026). PMID: 42265612 ↗
L3bCited in: Clinical Features and Variants
[246]
Patel AA, Nishat S, Joshi RB et al.. “Following Severe Pediatric Malaria, Epilepsy Screening Is Needed Even Among Children Without Coma: Findings From a Prospective Cohort Study.” Journal of central nervous system disease (2026). PMID: 42436689 ↗
L2bCited in: Clinical Features and Variants
[247]
Zhao W, Wang J, Du XY et al.. “Dihydroartemisinin-stachyose conjugate (sDHA) improves the oral bioavailability of dihydroartemisinin and antiemphalitic malaria effects.” Nanomedicine : nanotechnology, biology, and medicine (2026). PMID: 42331046 ↗
L3bCited in: Clinical Features and Variants
[248]
Luzolo Khote F, Raposo M, Maseko T et al.. “Prevalence of antimalarial drug resistance markers and factors associated with Plasmodium falciparum infection in asymptomatic children prior to rectal artesunate implementation in Kapolowe Health District, Democratic Republic of the Congo.” Malaria journal (2026). PMID: 42374417 ↗
L3bCited in: Clinical Features and Variants
[249]
Camara S, Buck A, Burrell M et al.. “Immunomodulation Therapy to Treat Severe Malaria With Multiple Organ Failure.” Critical care explorations (2026). PMID: 42644869 ↗
L4Cited in: Clinical Features and Variants
[250]
Okullo CO, Nakaziba R. “Community Knowledge, Self-Reported Prevalence, and Management of Epilepsy in Lira District: A Descriptive Cross-Sectional Study.” Neuropsychiatric disease and treatment (2026). PMID: 42444840 ↗
L3bCited in: Clinical Features and Variants
[251]
Accrombessi M, Assongba L, Khairallah C et al.. “Delivery strategies for malaria chemoprevention in the post-discharge management of children hospitalised with severe anaemia or severe malaria: protocol for a cluster randomised controlled implementation trial in Benin.” BMJ open (2026). PMID: 42665339 ↗
L5Cited in: Clinical Features and Variants
[252]
van Genderen PJJ, Fumarola M, Hassing RJ et al.. “SEVMALrisk: An Externally Validated Clinical Risk Score for Early Risk Stratification of Severe Imported Malaria.” Journal of travel medicine (2026). PMID: 42685242 ↗
L5Cited in: Clinical Features and Variants
[253]
Hwang J, Halsey ES, Plucinski MM et al.. “Extending the Duration of Artemether-Lumefantrine Treatment for Uncomplicated Plasmodium falciparum Malaria: Updated US Centers for Disease Control and Prevention Guidance Based on Review of Surveillance, Consultations, and Published Data.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 42616037 ↗
L5Cited in: Clinical Features and Variants
[254]
Basnyat B, Adhikari S, Shrestha P et al.. “Azithromycin with or without cefixime for suspected or culture-confirmed uncomplicated typhoid fever in Nepal, Bangladesh, and Pakistan (ACT-South Asia): a double-blind, parallel-group, randomised, placebo-controlled, phase 4 trial.” The Lancet. Infectious diseases (2026). PMID: 42624818 ↗
L1bCited in: Diagnosis and Workup
[255]
Ramalan M, Rabiu A, Jibril M et al.. “Optimizing intermittent preventive treatment for malaria in pregnancy: protocol for phase IV randomized controlled trial of sulphadoxine-pyrimethamine, dihydroartemisinin-piperaquine, and combination therapy in Northern Nigeria.” BMC pregnancy and childbirth (2026). PMID: 42432528 ↗
L1bCited in: Diagnosis and Workup
[256]
. “The effect of mefloquine dose on outcome of uncomplicated falciparum malaria treated with artesunate-mefloquine: a WWARN systematic review and individual patient data meta-analysis.” Malaria journal (2026). PMID: 42638106 ↗
L2aCited in: Diagnosis and Workup
[257]
Bouzayene A, Joste V, Candau T et al.. “Persistence of Plasmodium falciparum DNA detection after antimalarial treatment and the implication of gametocytes: a prospective cohort study in a non-endemic setting.” Microbiology spectrum (2026). PMID: 42684939 ↗
L2bCited in: Diagnosis and Workup
[258]
McHenry MS, Ayodo G, Marete I et al.. “Association of asymptomatic Plasmodium falciparum infections and its treatment with short-term cognitive performance in school-aged children: A prospective cohort study in western Kenya.” The Journal of infection (2026). PMID: 42617751 ↗
L2bCited in: Diagnosis and Workup
[259]
Segala FV, Ictho J, L'episcopia M et al.. “Effect of sulphadoxine-pyrimethamine resistance on birthweight and parasite persistence among women receiving intermittent preventive treatment for malaria in pregnancy in Northern Uganda: a directed acyclic graph-guided analysis.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42595091 ↗
L2bCited in: Diagnosis and Workup
[260]
Mortazavi SE, Lugaajju A, Tijani MK et al.. “Malaria exposure history shapes PD-1 expression across human B-cell subsets during acute Plasmodium falciparum infection.” BMC microbiology (2026). PMID: 42458286 ↗
L3bCited in: Diagnosis and Workup
[261]
Baina MT, Mouanga AM, Vouvoungui C et al.. “Low practical knowledge but high willingness to use malaria rapid diagnostic tests among healthcare workers in the Republic of Congo.” BMC public health (2026). PMID: 42576208 ↗
L3bCited in: Diagnosis and Workup
[262]
Sidi Omar SFN, Ngui R, Jiee SF et al.. “Low prevalence of sub-microscopic malaria among rural communities of an endemic area in Kapit Division, Malaysian Borneo.” Malaria journal (2026). PMID: 42437921 ↗
L3bCited in: Diagnosis and Workup
[263]
Huang M, Jia X, Wang X et al.. “Severe Plasmodium falciparum malaria with marked ADAMTS13 reduction and secondary microangiopathic features: A case report.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026). PMID: 42636958 ↗
L3bCited in: Diagnosis and Workup
[264]
Srivastava B, Anvikar A, Anvikar D et al.. “Prospective Assessment of the Performance of a Combi-Rapid Diagnostic Test to Accurately Diagnose Malaria and Detect C-Reactive Protein in Selected Settings in India.” The American journal of tropical medicine and hygiene (2026). PMID: 42480513 ↗
L3bCited in: Diagnosis and Workup
[265]
Imani-Musimwa P, Grant E, Mukadi-Bamuleka D et al.. “Challenges in managing ruptured ectopic pregnancy complicated by hemorrhagic shock in an Ebola treatment unit in DR Congo: first reported case.” Frontiers in medicine (2026). PMID: 42698519 ↗
L4Cited in: Diagnosis and Workup
[266]
Wazodan AM, Lamine MM, Alkassoum I et al.. “[Impact of introducing a fifth monthly cycle of seasonal malaria chemoprevention among children aged 3 to 59 months: a quasi-experimental difference-in-differences study in the Zinder Region, Niger].” The Pan African medical journal (2026). PMID: 42662648 ↗
L2bCited in: Diagnosis and Workup
[267]
Tandina F, Doumbo SN, Djimdé M et al.. “Malaria Vectors' Diversity and Seasonality in Sustaining Disease Transmission in an Endemic Area of Faladie, Mali.” Tropical medicine and infectious disease (2026). PMID: 42646793 ↗
L3bCited in: Diagnosis and Workup
[268]
Mensah BT, Otu H, Armah DNO et al.. “Submicroscopic Plasmodium falciparum Carriage and Molecular Markers of Antimalarial Drug Resistance Among Outpatients Attending Korle Bu Teaching Hospital, Ghana.” Tropical medicine and infectious disease (2026). PMID: 42506760 ↗
L3bCited in: Diagnosis and Workup
[269]
Konja BA, Agyapong NAF, Ocran EK et al.. “Targeting childhood malaria: insights from multi-country DHS data in Sub-Saharan Africa.” BMC pediatrics (2026). PMID: 42481992 ↗
L3bCited in: Diagnosis and Workup
[270]
O'Brien NF, Postels DG, Chimalizeni Y et al.. “Adjunctive Mechanical Ventilation or Intravenous Hypertonic Saline in Malawian Children with Cerebral Malaria and Highly Increased Brain Volume: A Randomized, Phase 3 Clinical Trial.” Neurocritical care (2026). PMID: 42230477 ↗
L1bCited in: Supportive Care and Complication Management
[271]
Ochanda PN, Aakvik A, Bangirana P et al.. “Severe malarial anaemia in childhood is associated with decreased long-term household wealth.” BMC public health (2025). PMID: 41291612 ↗
L2bCited in: Supportive Care and Complication Management
[272]
Balerdi-Sarasola L, Muñoz J, Fleitas P et al.. “Not all severe malaria cases are severe: Is it time to redefine severity criteria for malaria in non-endemic regions?” Travel medicine and infectious disease (2024). PMID: 39002737 ↗
L4Cited in: Supportive Care and Complication Management
[273]
Ma G, Hou C, Li Y et al.. “Global burden of childhood Burkitt lymphoma (1990-2021): epidemiological trends, regional disparities, and projections for 2035 from the Global Burden of Disease Study.” Frontiers in medicine (2025). PMID: 41070076 ↗
L3bCited in: Supportive Care and Complication Management
[274]
Doka Hélène KS, Ignatius E, Berinyuy M et al.. “Nonsurgical Neurological Emergencies in Children: A Cross-Sectional Study of Prevalence, Diagnosis, and Management.” Pediatric neurology (2025). PMID: 40609287 ↗
L3bCited in: Supportive Care and Complication Management
[275]
Moutombi Ditombi BC, Manomba Boulingui C, Mayandza C et al.. “Parasitic and fungal central nervous system infections in hospitalised adults living with HIV in Libreville, Gabon: clinical profiles to inform syndromic triage in resource limited settings.” AIDS research and therapy (2026). PMID: 41546100 ↗
L3bCited in: Supportive Care and Complication Management
[276]
Dagne A, Doumbe-Belisse P, Degefa T et al.. “Field evaluation of SumiLarv™ 2MR larvicide for controlling the invasive malaria vector Anopheles stephensi in Ethiopia: a randomised controlled trial.” Malaria journal (2026). PMID: 42681633 ↗
L1bCited in: Prevention and Screening
[277]
LaVerriere E, Kelley K, Dicko A et al.. “Genotypic analysis of Plasmodium falciparum malaria parasites in a clinical trial of RTS,S vaccination in combination with seasonal malaria chemoprevention.” Malaria journal (2026). PMID: 42393745 ↗
L2bCited in: Prevention and Screening
[278]
Ndung'u L, Muriithi B, Gitahi S et al.. “Regional Patterns and Temporal Trends of Pfdhfr and Pfdhps Markers of Antifolate Resistance in Plasmodium falciparum in East and West Africa, 2010-2025: A Systematic Review.” Acta tropica (2026). PMID: 42437651 ↗
L2aCited in: Prevention and Screening
[279]
Simanjuntak AMT, Wijayanto FPS, Nugraha RTH et al.. “Efficacy of dihydroartemisinin-piperaquine to prevent malaria and complication-related malaria during pregnancy compared to sulfadoxine-pyrimethamine: a systematic review, meta-analysis, and meta-regression.” Epidemiology and infection (2026). PMID: 42415480 ↗
L2aCited in: Prevention and Screening
[280]
Safari MS, Makori TO, Gicheru ET et al.. “A natural experiment in Kenya reveals durable immunosuppressive effects of early childhood malaria: a longitudinal cohort study.” eLife (2026). PMID: 42444449 ↗
L3bCited in: Prevention and Screening
[281]
Namubiru C, Mahmoudou S, Djida Y et al.. “Linking health literacy to malaria prevention and treatment behaviours: evidence from a community-based study in Gabon.” BMC health services research (2026). PMID: 42642735 ↗
L3bCited in: Prevention and Screening
[282]
Ewinetu MK, Mekonen Belay B, Abere Y. “Malaria prevention practice and associated factors among residents in Fogera district, Ethiopia, during the armed conflict between Amhara Fano forces and the federal government, 2025.” Malaria journal (2026). PMID: 42482058 ↗
L3bCited in: Prevention and Screening
[283]
Hicks JT, Munsey A, Mousa A et al.. “Disentangling patterns of community malaria transmission and burden using malaria prevalence among pregnant women attending antenatal care: a modelling study.” The Lancet. Microbe (2026). PMID: 42456694 ↗
L3bCited in: Prevention and Screening
[284]
Andriamasy EH, Razafimanantsoa H, Tiaray Harison M et al.. “Community health worker involvement across domains and national infectious disease programmes in rural Madagascar: evidence of fragmentation and determinants of engagement.” BMJ global health (2026). PMID: 42419867 ↗
L3bCited in: Prevention and Screening
[285]
Lequechane JD, Lopes LF, Gonçalves L et al.. “Field evaluation of 3-(N-acetyl-n-butyl) aminopropionic acid ethyl ester - IR3535 as a spatial repellent to control malaria: A Randomised, Before-After-Control-Intervention trial.” PloS one (2026). PMID: 42531228 ↗
L1bCited in: Prevention and Screening
[286]
Zhang T, Huang S, Ibinaiye T et al.. “Understanding the Dimensions of Caregiver-Perceived Seasonal Malaria Chemoprevention Delivery Quality in Nigeria: A Structural Equation Modeling Analysis of Door-to-Door Seasonal Malaria Chemoprevention.” The American journal of tropical medicine and hygiene (2026). PMID: 42641592 ↗
L3bCited in: Prevention and Screening
[287]
Glover AC, Koenker H, Niang EHA et al.. “Heterogeneity of use, access, and retention of insecticide-treated nets: Implications for subnational tailoring to maximise malaria control.” eLife (2026). PMID: 42623257 ↗
L5Cited in: Prevention and Screening
[288]
Sullivan DJ. “Monoclonal antibody CIS43LS sets the bar for long-acting malaria protection.” The Journal of clinical investigation (2026). PMID: 42606125 ↗
L5Cited in: Prevention and Screening
[289]
Sha T, Liao Z, Yuan T et al.. “Imported mosquito-borne infectious diseases in travellers and migrants: Global patterns, clinical overlap, and prevention gaps-an umbrella review of 21 systematic reviews.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42810509 ↗
L2aCited in: Clinical Features and Variants
[290]
Rehman AU, Nnaemeka V, Nasir MH et al.. “Efficacy and Response of R21/Matrix-M in Malaria Vaccine: A Systematic Review and Meta-Analysis of Clinical Trials.” Vaccines (2026). PMID: 42797644 ↗
L2aCited in: Clinical Features and Variants
[291]
Ortiz-Fernández M, Balerdi-Sarasola L, Ciminelli F et al.. “Community-acquired coinfections in adults with severe imported malaria: a systematic review and meta-analysis.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42754092 ↗
L2aCited in: Clinical Features and Variants
[292]
Mellencamp KA, Namazzi R, Batte A et al.. “Long-term mortality and risk of chronic kidney disease in children following severe malaria complicated by acute kidney injury: a prospective observational study.” The Lancet. Global health (2026). PMID: 42575118 ↗
L2bCited in: Clinical Features and Variants
[293]
Niu B, Wang R, Tian H et al.. “Clinical contribution of mNGS in the diagnosis and management of imported falciparum malaria in a malaria-free region: a five-case series from northern China.” Frontiers in cellular and infection microbiology (2026). PMID: 42851315 ↗
L4Cited in: Clinical Features and Variants
[294]
Peng K, Gong W, Dong X et al.. “Epidemiological and clinical characteristics of imported malaria patients admitted to a specialized hospital: a retrospective study (2021- June 2026).” Frontiers in cellular and infection microbiology (2026). PMID: 42835030 ↗
L4Cited in: Clinical Features and Variants
[295]
Negash AA, Woudineh MT, Mohammed KH et al.. “Emerging predominance of Plasmodium vivax and its contribution to severe malaria in Central Ethiopia: a mixed retrospective-prospective study from two tertiary hospitals.” BMC infectious diseases (2026). PMID: 42806321 ↗
L3bCited in: Clinical Features and Variants
[296]
Pikor D, Duda J, Ciechanowski M et al.. “Clinical Spectrum and Admission Correlates of Complicated Imported Malaria in Polish Travellers: An 11-Year Retrospective Analysis with Geographic Mapping of Travel Destinations.” Journal of clinical medicine (2026). PMID: 42796040 ↗
L3bCited in: Clinical Features and Variants
[297]
Oduro D, Konadu EA, Obiri D et al.. “Longitudinal dynamics of angiopoietin-1, angiopoietin-2 and soluble thrombomodulin during recovery from paediatric cerebral malaria in Ghana.” Acta tropica (2026). PMID: 42838407 ↗
L2bCited in: Clinical Features and Variants
[298]
Bekolo CE, Ngouenko N, Dipepa Nwall ELN et al.. “Assessing the impact of routine malaria vaccination on total disease burden in Cameroon: a nationwide difference‑in‑differences analysis using health district surveillance data (2023-2025).” Tropical diseases, travel medicine and vaccines (2026). PMID: 42823750 ↗
L2bCited in: Clinical Features and Variants
[299]
Kamphuis AEM, Salvadori N, Mujuru HA et al.. “Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial.” The lancet. HIV (2026). PMID: 42705257 ↗
L4Cited in: Clinical Features and Variants
[300]
Seo JW, Kim DY, Yun NR et al.. “Postdeployment Plasmodium Infections among South Korean Soldiers Receiving Mefloquine Chemoprophylaxis in South Sudan.” The American journal of tropical medicine and hygiene (2026). PMID: 42810327 ↗
L3bCited in: Clinical Features and Variants
[301]
Tumlinson K, Rabemanantsoa A, Rahantanirina S et al.. “Wings of access: a cluster RCT on drone-based medical commodity delivery in remote Madagascar.” BMJ global health (2026). PMID: 42810815 ↗
L1bCited in: Diagnosis and Workup
[302]
Mombo-Ngoma G, Meneguim A, Zoleko Manego R et al.. “Association between number of previous malaria episodes and treatment failure among children and adults with laboratory-confirmed Plasmodium infection treated with pyronaridine-artesunate in Gabon: a retrospective cohort study.” Malaria journal (2026). PMID: 42760579 ↗
L2bCited in: Diagnosis and Workup
[303]
Rotich B, Kimachas E, Kipkoech J et al.. “Seasonal malaria chemoprevention effectiveness and drug resistance in Plasmodium falciparum: a matched parallel cohort study, Kenya.” Bulletin of the World Health Organization (2026). PMID: 42819667 ↗
L3bCited in: Diagnosis and Workup
[304]
Ndlovu Z, Burton R, Steenssens M et al.. “Task shifting of point-of-care testing to lay health workers in rural primary health facilities in Nsanje, Malawi.” Global health action (2026). PMID: 42802921 ↗
L3bCited in: Diagnosis and Workup
[305]
Mwenda M, Oliveira R, Mambwe B et al.. “Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study.” The Lancet. Infectious diseases (2026). PMID: 42843387 ↗
L3bCited in: Diagnosis and Workup
[306]
Zeleke AJ, Bezabih MK, Ejigu LA et al.. “Data-driven diagnostic reform in Ethiopia's transition to pLDH-based malaria rapid diagnostic tests amid rising pfhrp2/3 deletions: a multisite, facility-based, cross-sectional study.” The Lancet. Microbe (2026). PMID: 42790453 ↗
L3bCited in: Diagnosis and Workup
[307]
Tacoli C, Grimée M, Smith L et al.. “Validation of serological markers of recent exposure to Plasmodium vivax in Cambodia: a longitudinal cohort and cross-sectional study.” The Lancet regional health. Western Pacific (2026). PMID: 42718914 ↗
L3bCited in: Diagnosis and Workup
[308]
Cornet A, Schwob JM, Roussel C et al.. “Persistent non-viable Plasmodium falciparum parasitemia mimicking artesunate treatment failure and unmasking functional hyposplenism.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42562125 ↗
L4Cited in: Diagnosis and Workup

Malaria